Solid state forms of a ULK inhibitor

Abstract

Provided herein, in part, are solid-state salt forms of the compound represented by Formula (I), or a solvate thereof, pharmaceutical compositions comprising the solid-state salt forms, processes of making the solid-state salt forms, and methods of using the solid-state salt forms.

Description

Attorney Docket No. DCP-147WOSOLID STATE FORMS OF ULK INHIBITORSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63 / 703,382, filed October 04, 2024, which is incorporated herein by reference in its entirety.TECHNICAL FIELD

[0002] The present disclosure relates to salt forms of the compound represented by Formula (I), or a solvate thereof, their pharmaceutical compositions, processes for their preparation, and methods for their use.BACKGROUND

[0003] Autophagy is a process that enables cells to recycle cellular organelles, proteins, stored lipids, glucagon, and other materials for the purpose of generating nutrients under periods of stress. These cellular contents are recycled by engulfment in vesicles called autophagosomes. Autophagosomes subsequently merge with lysosomes that degrade the autophagosomal contents for recycling of nutrients to the cell. Tumor cells are prone to activate autophagy, as these cells have a high metabolic demand, experience cellular stress, and frequently are in hypoxic environments with limited blood flow and nutrient supply. Moreover, chemotherapy and targeted anti -cancer therapies have been shown to induce autophagy as a treatment resistance mechanism, and combination of autophagy inhibition (by genetic loss of function mutations in autophagy genes or by pharmacologic means) with chemotherapeutic regimens has been shown to suppress tumor growth and trigger tumor cell apoptosis to a greater extent than single agent chemotherapy alone.

[0004] Mutant Ras proteins drive approximately 30 percent of all human cancers - including 95 percent of pancreatic cancers, 45 percent of colorectal cancers, and 30% of lung cancers, and treatment of these mutant Ras cancers is currently an area of high unmet medical need. Mutant Ras cancers are highly proliferative and depend on basal levels of autophagy for survival, suggesting that inhibition of autophagy in these “autophagy addicted” cancers is a viable therapeutic approach.

[0005] Currently, the most widely used autophagy inhibitors are chloroquine and hydroxychloroquine, which are well-known anti-malarial agents. These anti-malarials have been1IPTS / 200140885.2Attorney Docket No. DCP-147WO thought to block autophagy by being sequestered in the lysosomal compartment, raising the pH of these lysosomes and thereby inactivating proteases that degrade and recycle nutrients. These anti-malarial agents have multiple mechanisms of action beyond inhibiting lysosomes and are known to induce retinopathies in patients. Hence there is a need for more targeted agents which selectively block autophagy and do not exhibit the toxicities of these anti-malarial agents. Unc- 51-like autophagy-activating kinase 1 (ULK1) kinase is the initiating protein of autophagy and is a serine / threonine kinase. The ULK1 kinase complex is activated in response to cellular stress including nutrient deprivation and energy depletion. Nutrient deprivation activates ULK kinase activity through inhibition of mTORCl, and energy depletion activates ULK kinase activity through activation by AMP-activated protein kinase AMPK. Importantly, kinase dead mutants of ULK kinase block initiation of canonical autophagy, suggesting that small molecule inhibitors of ULK kinase activity would be able to block autophagy.

[0006] Further mechanistic studies have shown that genetic deletion of ULK 1 inhibits autophagy in cancer cells, relieving FOX3A turn-over and upregulation of the pro-apoptotic protein PUMA. In addition to classical activation of canonical autophagy, ULK1 kinase activity has been shown to be required for Bcl-2-L-13 mediated mitophagy (autophagy of damaged mitochondria). ULK1 and ULK2 kinases have also been demonstrated to rewire cancer cell glucose metabolism which favors increases in the reducing agent NADPH leading to a reduction in toxic reactive oxygen species (ROS). ULK inhibitors may also find utility in blocking these noncanonical pro-tumoral activities of ULK.

[0007] Autophagy is also upregulated in host cells and tissues in cancer. Autophagy in pancreatic tissue stellate cells was demonstrated to support tumor growth. Pancreatic stellate cells were shown to support pancreatic cancer tumor metabolism through autophagic alanine secretion. Inhibition of host tissue autophagy was demonstrated to lead to a depletion in circulating arginine (a required amino acid for tumor metabolism and growth) through liver - mediated increases in arginase secretion. Activation of ULK 1 kinase was also shown to inactivate the STING pathway in immune cells through inhibitory phosphorylation of STING, mediating a negative feedback mechanism for limiting an innate immune cell response mediated by interferons. Thus, not only is autophagy activated in tumor cells (cancer cell autonomous), but also in other cells in the tumor microenvironment or host tissues (cancer call nonautonomous) to support tumor survival and growth.2IPTS / 200140885.2Attorney Docket No. DCP-147WO

[0008] Mutant Ras cancers are addicted to autophagy. In pancreatic cancer, mutant Ras signals predominantly through the MAP kinase pathway. Mutant Ras activates RAF kinases, which in turn activate mitogen-activated protein kinase (MEK) kinases, which finally activate ERK kinases: mutant Ras -> RAF -> MEK -> ERK. Despite mutant Ras signaling through the MAP kinase pathway, inhibitors of this pathway have provided no or little clinical benefit in clinical trials when used as single agents. It has been recently reported that inhibition of the MAP kinase pathway induces autophagy as a compensatory adaptive stress response resistance mechanism. When MEK inhibitors were combined with the autophagy inhibitor hydroxychloroquine, there was synergistic activity leading to regression of a number of mutant Ras or mutant BRAE cancers. Similarly, when ERK inhibitors were combined with the autophagy inhibitor hydroxychloroquine or chloroquine, there was synergistic activity leading to inhibition of mutant Ras pancreatic cancers. It has been demonstrated that genetic depletion of RAF kinases (CRAF and BRAF) led to synergistic anti-tumor activity in mutant Ras cancer cell lines when autophagy was also genetically depleted. In composite, recent publications highlight that dual inhibition of the RAS / MAPK pathway and the autophagy pathway in mutant Ras cancers is a promising treatment regimen for patients with mutant Ras cancers. It has also been demonstrated that other targeted therapies and chemotherapeutic agents activate tumor autophagy as a resistance mechanism; hence there is rationale for combining such targeted therapeutics or chemotherapeutic agents with inhibitors of autophagy.

[0009] It has also been demonstrated that tumor driver receptor tyrosine kinases (RTKs) can modulate autophagy, and that inhibitors of RTKs also activate autophagy through the same mTORCl and AMP kinase pathways as do inhibitors of mutant RAS or RAF. Inhibitors of mutant oncogenic KIT kinase, inhibitors of oncogenic EGFR kinase, and inhibitors of oncogenic FLT3 kinase are known to activate autophagy as an adaptive stress response resistance mechanism.

[0010] There is a need for new targeted therapies which inhibit autophagy and can be used in combination with RTK / RAS / MAPK pathway inhibitors, chemotherapeutic agents, and / or other targeted therapeutics.

[0011] Different solid-state forms, including salts and solvated forms, of an active pharmaceutical ingredient may have different properties. Different solid-state forms, salts and solvates of an active pharmaceutical ingredient may give rise to a variety of other polymorphs or3IPTS / 200140885.2Attorney Docket No. DCP-147WO crystalline forms, co-crystals, solvates and other solid-state forms with improved properties.Such improved properties, e.g., differences in physical, mechanical, chemical, or physicochemical properties, can provide solid-state forms with desirable properties which enable their clinical and commercial development. Improved beneficial properties in, but not limited to, stability, solubility, melting point, hardness, hygroscopicity, flowability, or compressibility, can result, for example, in improvement in bioavailability, dissolution profile, process reproducibility, ease of purification, ease of handling, ease of manufacturing, ease of processing, storage stability, or shelf-life. Improved properties of a solid-state form may also enable for better formulation optimization, leading to development and commercialization of superior drug products otherwise not available to patients. There is a need for new solid-state forms with improved properties for use in the pharmaceutical industry and leading to improved drugs available to patients.SUMMARY

[0012] Described herein, in part, are salt forms of the compound represented by Formula (I):or a solvate thereof, pharmaceutical compositions comprising the salt forms, processes of making the salt forms, and methods of using the salt forms.

[0013] In some embodiments, the salt is selected from the group consisting of hydrobromide, hydrochloride, napadisylate, sulfate, edisylate, cyclamate, tosylate, thiocyanate, mesylate, napsylate, besylate, oxalate, aspartate, maleate, pamoate, malonate, gentisate, salicylate, tartrate, fumarate, mandelate, malate, benzoate, succinate, and acetate.

[0014] In some embodiments, provided herein are solid-state salt forms of the compound represented by Formula (I):4IPTS / 200140885.2Attorney Docket No. DCP-147WOor a solvate thereof, pharmaceutical compositions comprising the solid-state salt forms, processes of making the solid-state salt forms, and methods of using the solid-state salt forms.

[0015] Provided herein, in part, are methods of preparing solid-state salt forms of the compound represented by Formula (I), or a solvate thereof, and the use of these solid-state salt forms for the preparation of pharmaceutical compositions and / or pharmaceutical formulations of the solid-state form of the compound represented by Formula (I), or a solvate thereof.

[0016] Provided herein, in part, are methods of treating diseases and conditions including, but not limited to, cancer, such as gastrointestinal stromal tumors, esophageal cancer, gastric cancer, melanomas, gliomas, glioblastomas, ovarian cancer, bladder cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, osteosarcomas, Ewing sarcoma, multiple myelomas, cervical carcinomas, cancers that are metastatic to bone, papillary thyroid carcinoma, non-small cell lung cancer, colorectal cancer, acute myeloid leukemia, relapsed acute myeloid leukemia, refractory acute myeloid leukemia, myelodysplastic syndrome, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, and mantle cell lymphoma.

[0017] In another embodiment, provided herein is a method of treating a tumor in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a solid-state salt form described herein or pharmaceutically acceptable solvates thereof, or of a pharmaceutical composition described herein.

[0018] In some embodiments, the methods further comprise administering to the patient one or more additional therapeutic agents.

[0019] Also provided herein, in part, are solid-state salt forms of the compound represented by Formula (I), or a solvate thereof, or a composition thereof, for use in therapy.5IPTS / 200140885.2Attorney Docket No. DCP-147WO

[0020] Provided herein, in part, are solid-state salt forms of the compound represented by Formula (I), or a solvate thereof, or a composition thereof, for use in treating diseases and conditions including, but not limited to, cancer, such as gastrointestinal stromal tumors, esophageal cancer, gastric cancer, melanomas, gliomas, glioblastomas, ovarian cancer, bladder cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, osteosarcomas, Ewing sarcoma, multiple myelomas, cervical carcinomas, cancers that are metastatic to bone, papillary thyroid carcinoma, non-small cell lung cancer, colorectal cancer, acute myeloid leukemia, relapsed acute myeloid leukemia, refractory acute myeloid leukemia, myelodysplastic syndrome, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, and mantle cell lymphoma.

[0021] In another embodiment, provided herein are solid-state salt forms described herein or pharmaceutically acceptable solvates thereof, or of pharmaceutical compositions described herein for use in treating a tumor in a patient in need thereof.

[0022] In some embodiments, the compound or composition for use further comprises administering to the patient one or more additional therapeutic agents.BRIEF DESCRIPTION OF THE DRAWINGS

[0023] FIG. 1A shows exemplary X-ray powder diffractometry (XRPD) diffractograms of the salt screen hydrobromic acid experiments (post maturation).

[0024] FIG. IB shows exemplary XRPD diffractograms of the salt screen hydrobromic acid experiments (post 40 °C / 75% RH).

[0025] FIG. 1C shows an exemplary therm ogravimetric (“TG”) / differential scanning calorimetry (“DSC”) analysis thermogram of hydrobromide Form II from ethyl acetate.

[0026] FIG. ID shows an exemplary differential scanning calorimetry (DSC) thermogram of hydrobromide Form II from ethyl acetate; 1stheating cycle (20 to 230 °C).

[0027] FIG. IE shows aXH nuclear magnetic resonance (NMR) spectrum of hydrobromide Form II from ethyl acetate.

[0028] FIG. IF shows an exemplary TG / DSC thermogram of hydrobromide Form I.

[0029] FIG. 1G shows an exemplary DSC thermogram of hydrobromide Form I.

[0030] FIG. 1H shows a 'H NMR spectrum of hydrobromide Form I.

[0031] FIG. 1J shows XRPD diffractogram of hydrobromide Form I from 2-MeTHF(post maturation).6IPTS / 200140885.2Attorney Docket No. DCP-147WO

[0032] FIG. 2A shows an exemplary XRPD diffractogram of hydrobromide Form II.

[0033] FIG. 2B shows an exemplary TG / DSC thermogram of hydrobromide Form II.

[0034] FIG. 2C shows an exemplary DSC thermogram of the hydrobromide Form II; 1stheating cycle (20 to 230 °C).

[0035] FIG. 2D shows a dynamic vapor sorption (DVS) isotherm for hydrobromide Form II.

[0036] FIG. 2E shows a DVS kinetic plot for hydrobromide Form II.

[0037] FIG. 2F shows exemplary XRPD diffractogram s of hydrobromide Form II post- DVS.

[0038] FIG. 2G shows a 'H NMR spectrum hydrobromide Form II.

[0039] FIG. 2H shows exemplary XRPD diffractograms of hydrobromide Form II poststability.

[0040] FIG. 3A shows exemplary XRPD diffractograms of the salt screen hydrochloric acid experiments (post maturation).

[0041] FIG. 3B shows exemplary XRPD diffractograms of the salt screen hydrochloric acid experiments (post 40 °C / 75% RH).

[0042] FIG. 3C shows an exemplary TG / DSC thermogram of hydrochloric Form I from ethyl acetate.

[0043] FIG. 3D shows a 'H NMR spectrum of hydrochloric Form I from ethyl acetate.

[0044] FIG. 3E shows an exemplary XRPD diffractogram of hydrochloric Form I from ethyl acetate (post maturation).

[0045] FIG. 4A shows exemplary XRPD diffractograms of the salt screen 1,5- naphthalenedisulfonic acid experiments (post maturation).

[0046] FIG. 4B shows exemplary XRPD diffractograms of the salt screen 1,5- naphthalenedi sulfonic acid experiments (post 40 °C / 75% RH).

[0047] FIG. 4C shows an exemplary TG / DSC thermogram of napadisylate Form I from 2-MeTHF.

[0048] FIG. 4D shows an exemplary DSC thermogram of the napadisylate Form I from 2-MeTHF; 1st heating cycle (20 to 230 °C).

[0049] FIG. 4E shows a 'H NMR spectrum of napadisylate Form I from 2-MeTHF.

[0050] FIG. 4F shows an exemplary XRPD diffractogram of napadisylate Form I.7IPTS / 200140885.2Attorney Docket No. DCP-147WO

[0051] FIG. 5A shows exemplary XRPD diffractograms of the salt screen sulfuric acid experiments (post maturation).

[0052] FIG. 5B shows exemplary XRPD diffractograms of the salt screen sulfuric acid experiments (post 40 °C / 75% RH).

[0053] FIG. 5C shows an exemplary TG / DSC thermogram of sulfate Form I from acetone.

[0054] FIG. 5D shows a 'H NMR spectrum of sulfate Form I from acetone.

[0055] FIG. 5E shows an exemplary TG / DSC thermogram of sulfate Form II from ethanol.

[0056] FIG. 5F shows a 'H NMR spectrum of sulfate Form II from ethanol.

[0057] FIG. 5G shows an exemplary XRPD diffractogram of sulfate Form I from acetone(post 40 °CZ 75% RH).

[0058] FIG. 5H shows exemplary XRPD diffractograms of sulfate Form II from ethanol (post 40 °C / 75% RH).

[0059] FIG. 6A shows exemplary XRPD diffractograms of the salt screen 1,2 ethanedisulfonic acid experiments (post maturation).

[0060] FIG. 6B shows exemplary XRPD diffractograms of the salt screen 1,2 ethanedi sulfonic acid experiments (post 40 °C / 75% RH).

[0061] FIG. 6C shows an exemplary TG / DSC thermogram of edisylate Form I from acetone.

[0062] FIG. 6D shows an exemplary DSC thermogram of the edisylate Form I from acetone; 1stheating cycle (20 to 220 °C).

[0063] FIG. 6E shows a 'H NMR spectrum of edisylate Form I from acetone.

[0064] FIG. 6F shows an exemplary XRPD diffractogram of edisylate Form I from 2-MeTHF (post 40 °C / 75% RH).

[0065] FIG. 6G shows an exemplary XRPD diffractogram of edisylate Form II from ethyl acetate (post maturation).

[0066] FIG. 6H shows an exemplary XRPD diffractogram of edisylate Form III from the anti-solvent experiment (post maturation).

[0067] FIG. 6J shows an exemplary XRPD diffractogram of edisylate Form IV from the anti-solvent experiment (post 40 °C / 75% RH).8IPTS / 200140885.2Attorney Docket No. DCP-147WO

[0068] FIG. 6K shows an exemplary TG / DSC thermogram of edisylate Form IV from the anti-solvent experiment.

[0069] FIG. 6L shows a 'H NMR spectrum of edisylate Form IV from the anti-solvent experiment.

[0070] FIG. 7A shows exemplary XRPD diffractograms of the salt screen cyclamic acid experiments (post maturation).

[0071] FIG. 7B shows exemplary XRPD diffractograms of the salt screen cyclamic acid experiments (post 40 °C / 75% RH).

[0072] FIG. 7C shows an exemplary TG / DSC thermogram of cyclamate Form I from acetone.

[0073] FIG. 7D shows a1H NMR spectrum of cyclamate Form I from acetone.

[0074] FIG. 7E shows an exemplary XRPD diffractogram of cyclamate Form I from ethyl acetate (post 40 °C / 75% RH).

[0075] FIG. 7F shows an exemplary XRPD diffractogram of cyclamate Form II from the antisolvent experiment (post 40 °CZ 75% RH).

[0076] FIG. 7G shows a 'H NMR spectrum of cyclamate Form II from the anti-solvent experiment.

[0077] FIG. 8A shows exemplary XRPD diffractograms of the salt screen p- toluenesulfonic acid experiments (post maturation).

[0078] FIG. 8B shows exemplary XRPD diffractograms of the salt screen p- toluenesulfonic acid experiments (post 40 °C / 75% RH).

[0079] FIG. 8C shows an exemplary TG / DSC thermogram of tosylate Form I from 2- MeTHF.

[0080] FIG. 8D shows an exemplary DSC thermogram of the tosylate Form I from acetone; 1stheating cycle (20 to 200 °C).

[0081] FIG. 8E shows a 'H NMR spectrum of tosylate Form I from 2-MeTHF.

[0082] FIG. 8F shows an exemplary XRPD diffractogram of tosylate Form I from 2-MeTHF (post maturation).

[0083] FIG. 9A shows exemplary XRPD diffractograms of the salt screen thiocyanic acid experiments (post maturation).9IPTS / 200140885.2Attorney Docket No. DCP-147WO

[0084] FIG. 9B shows exemplary XRPD diffractogr ms of the salt screen thiocyanic acid experiments (post 40 °C / 75% RH).

[0085] FIG. 9C shows an exemplary TG / DSC thermogram of thiocyanate Form I from DCM.

[0086] FIG. 9D shows an exemplary XRPD diffractogram of thiocyanate Form I from DCM (post 40 °C / 75% RH).

[0087] FIG. 10A shows exemplary XRPD diffractograms of the salt screen methanesulfonic acid experiments (post maturation).

[0088] FIG. 10B shows exemplary XRPD diffractograms of the salt screen methanesulfonic acid experiments (post 40 °C / 75% RH).

[0089] FIG. 10C shows an exemplary TG / DSC thermogram of mesylate Form I from ethanol.

[0090] FIG. 10D shows an exemplary DSC thermogram of the mesylate Form I from ethanol; 1stheating cycle (20 to 230 °C).

[0091] FIG. 10E shows a1H NMR spectrum of mesylate Form I from ethanol.

[0092] FIG. 10F shows an exemplary XRPD diffractogram of mesylate Form I from ethanol (post maturation).

[0093] FIG. 10G shows an exemplary XRPD diffractogram of mesylate Form II from ethyl acetate (post maturation).

[0094] FIG. 11 A shows exemplary XRPD diffractograms of the salt screen naphthal ene- 2-sulfonic acid experiments (post maturation).

[0095] FIG. 1 IB shows exemplary XRPD diffractograms of the salt screen naphthalene- 2-sulfonic acid experiments (post 40 °C / 75% RH).

[0096] FIG. 11C shows an exemplary TG / DSC thermogram of napsylate Form I from 2- MeTHF.

[0097] FIG. 1 ID shows an exemplary DSC thermogram of the napsylate Form I from 2- MeTHF; 1stheating cycle (20 to 200 °C).

[0098] FIG. 1 IE shows a 'H NMR spectrum of napsylate Form I from 2-MeTHF.

[0099] FIG. 1 IF shows an exemplary XRPD diffractogram of napsylate Form I.[000100] FIG. 12A shows exemplary XRPD diffractograms of the salt screen benzenesulfonic acid experiments (post maturation).10IPTS / 200140885.2Attorney Docket No. DCP-147WO[000101] FIG. 12B shows exemplary XRPD diffractograms of the salt screen benzenesulfonic acid experiments (post 40 °CZ 75% RH).[000102] FIG. 12C shows an exemplary TG / DSC thermogram of besylate Form I from 2- MeTHF.[000103] FIG. 12D shows an exemplary DSC thermogram of the besylate Form I from 2- MeTHF; 1st heating cycle (20 to 200 °C).[000104] FIG. 12E shows aNMR spectrum of besylate Form I from 2-MeTHF.[000105] FIG. 12F shows an exemplary XRPD diffractogram of besylate Form I from 2-MeTHF (post 40 °C / 75% RH).[000106] FIG. 13 A shows exemplary XRPD diffractograms of the salt screen oxalic acid experiments (post maturation).[000107] FIG. 13B shows exemplary XRPD diffractograms of the salt screen oxalic acid experiments (post 40 °C / 75% RH).[000108] FIG. 13C shows an exemplary TG / DSC thermogram of oxalate Form III from 2- MeTHF.[000109] FIG. 13D shows a 'H NMR spectrum of oxalate Form III from 2-MeTHF.[000110] FIG. 13E shows an exemplary XRPD diffractogram of oxalate Form I from ethyl acetate (post maturation).[000111] FIG. 13F shows an exemplary XRPD diffractogram of oxalate Form II from MEK (post maturation).[000112] FIG. 13G shows an exemplary XRPD diffractogram of oxalate Form III from 2- MeTHF (post 40 °C / 75% RH).[000113] FIG. 14A shows exemplary XRPD diffractograms of the salt screen L-aspartic acid experiments (post maturation).[000114] FIG. 14B shows exemplary XRPD diffractograms of the salt screen L-aspartic acid experiments (post 40 °C / 75% RH).[000115] FIG. 14C shows an exemplary XRPD diffractogram of aspartate Form I from DCM (post maturation).[000116] FIG. 15A shows exemplary XRPD diffractograms of the salt screen maleic acid experiments (post maturation).11IPTS / 200140885.2Attomey Docket No. DCP-147WO[000117] FIG. 15B shows exemplary XRPD diffractograms of the salt screen maleic acid experiments (post 40 °C / 75% RH).[000118] FIG. 15C shows an exemplary XRPD diffractogram of maleate Form I from 2- MeTHF (post maturation).[000119] FIG. 15D shows an exemplary XRPD diffractogram of maleate Form II from DCM (post maturation).[000120] FIG. 16A shows exemplary XRPD diffractograms of the salt screen phosphoric acid experiments (post maturation).[000121] FIG. 16B shows exemplary XRPD diffractograms of the salt screen phosphoric acid experiments (post 40 °C / 75% RH).[000122] FIG. 16C shows an exemplary TG / DSC thermogram of phosphate material from acetone.[000123] FIG. 17A shows exemplary XRPD diffractograms of the salt screen ethanesulfonic acid experiments (post maturation).[000124] FIG. 17B shows exemplary XRPD diffractograms of the salt screen ethanesulfonic acid experiments (post 40 °C / 75% RH).[000125] FIG. 18A shows exemplary XRPD diffractograms of the salt screen pamoic acid experiments (post maturation).[000126] FIG. 18B shows exemplary XRPD diffractograms of the salt screen pamoic acid experiments (post 40 °C / 75% RH).[000127] FIG. 18C shows an exemplary TG / DSC thermogram of pamoate Form I from 2-MeTHF.[000128] FIG. 18D shows a 'H NMR spectrum of pamoate Form I from 2-MeTHF.[000129] FIG. 18E shows an exemplary TG / DSC thermogram of pamoate Form II from ethanol.[000130] FIG. 18F shows a 'H NMR spectrum of pamoate Form II from ethanol.[000131] FIG. 18G shows an exemplary XRPD diffractogram of pamoate Form I from 2-MeTHF (post maturation).[000132] FIG. 18H shows an exemplary XRPD diffractogram of pamoate Form II from ethanol (post 40 °C / 75% RH).12IPTS / 200140885.2Attorney Docket No. DCP-147WO[000133] FIG. 19A shows exemplary XRPD diffractograms of the salt screen glutaric acid experiments (post maturation).[000134] FIG. 19B shows exemplary XRPD diffractograms of the salt screen glutaric acid experiments (post 40 °C / 75% RH).[000135] FIG. 20A shows exemplary XRPD diffractograms of the salt screen malonic acid experiments (post maturation).[000136] FIG. 20B shows exemplary XRPD diffractograms of the salt screen malonic acid experiments (post 40 °C / 75% RH).[000137] FIG. 20C shows an exemplary XRPD diffractogram of malonate Form I from 2- MeTHF (post maturation).[000138] FIG. 21A shows exemplary XRPD diffractograms from the salt screen gentisic acid experiments (post maturation).[000139] FIG. 2 IB shows exemplary XRPD diffractograms of the salt screen gentisic acid experiments (post 40 °C / 75% RH).[000140] FIG. 21C shows an exemplary TG / DSC thermogram of gentisate Form I fromDCM[000141] FIG. 2 ID shows a 'H NMR spectrum of gentisate Form I from DCM.[000142] FIG. 2 IE shows exemplary XRPD diffractograms of gentisate Form II (post maturation).[000143] FIG. 2 IF shows exemplary XRPD diffractograms of gentisate Form II (post 40 °C / 75% RH).[000144] FIG. 21G shows an exemplary TG / DSC thermogram of gentisate Form II.[000145] FIG. 21H shows a 'H NMR spectrum of gentisate Form II.[000146] FIG. 21 J shows an exemplary XRPD diffractogram of gentisate Form I from DCM (post 40 °CZ 75% RH).[000147] FIG. 22A shows exemplary XRPD diffractograms of the salt screen salicylic acid experiments (post maturation).[000148] FIG. 22B shows exemplary XRPD diffractograms of the salt screen salicylic acid experiments (post 40 °C / 75% RH).[000149] FIG. 22C shows an exemplary TG / DSC thermogram of salicylate Form I from 2- MeTHF.13IPTS / 200140885.2Attorney Docket No. DCP-147WO[000150] FIG. 22D shows aXH NMR spectrum of salicylate Form I from 2-MeTHF.[000151] FIG. 22E shows an exemplary TG / DSC thermogram of salicylate Form II fromDCM.[000152] FIG. 22F shows aNMR spectrum of salicylate Form II from DCM.[000153] FIG. 22G shows an exemplary XRPD diffractogram of salicylate Form I from 2-MeTHF (post maturation).[000154] FIG. 22H shows an exemplary XRPD diffractogram of salicylate Form II from DCM (post maturation).[000155] FIG. 23A shows exemplary XRPD diffractogram s of the salt screen DL-tartaric acid experiments (post maturation).[000156] FIG. 23B shows exemplary XRPD diffractograms of the salt screen DL-tartaric acid experiments (post 40 °C / 75% RH).[000157] FIG. 23 C shows an exemplary TG / DSC thermogram of tartrate Form I from ethanol.[000158] FIG. 23D shows aJH NMR spectrum of tartrate Form I from ethanol.[000159] FIG. 24A shows exemplary XRPD diffractograms from DL-tartaric acid, D- tartaric acid and L-tartaric acid experiments.[000160] FIG. 24B shows an exemplary XRPD diffractogram for tartrate Form I.[000161] FIG. 25A shows an exemplary TG / DSC thermogram of tartrate Form II.[000162] FIG. 25B shows aNMR spectrum of tartrate Form II.[000163] FIG. 25C shows an exemplary XRPD diffractogram for tartrate Form II.[000164] FIG. 26A shows exemplary XRPD diffractograms of tartrate Form III.[000165] FIG. 26B shows an exemplary TG / DSC thermogram of tartrate Form III.[000166] FIG. 26C shows an exemplary DSC thermogram of the tartrate Form III; 1stheating cycle (20 to 200 °C).[000167] FIG. 26D shows a DVS isotherm for tartrate Form III.[000168] FIG. 26E shows a DVS kinetic plot for tartrate Form III.[000169] FIG. 26F shows exemplary XRPD diffractograms of tartrate Form III post-DVS.[000170] FIG. 26G shows aJH NMR spectrum tartrate Form III.[000171] FIG. 26H shows exemplary XRPD diffractograms of tartrate Form III poststability.14IPTS / 200140885.2Attorney Docket No. DCP-147WO[000172] FIG. 26J shows an exemplary XRPD diffractogram of tartrate Form III [000173] FIG. 27A shows an exemplary XRPD diffractogram of amorphous tartrate. [000174] FIG. 27B shows exemplary XRPD diffractograms of amorphous tartrate poststability conditions.[000175] FIG. 27C shows a TG / DSC thermogram of amorphous tartrate.[000176] FIG. 28A shows a TG / DSC thermogram of tartrate Form IV.[000177] FIG. 28B shows a DSC thermogram of tartrate Form IV (first heat cycle 20 to 180°C).[000178] FIG. 28C shows a DSC thermogram of tartrate Form IV (cool cycle 180-20 °C).[000179] FIG. 28D shows a DSC thermogram of tartrate Form IV (second heat cycle 20 to190 °C).[000180] FIG. 28E shows aNMR spectrum tartrate Form IV.[000181] FIG. 28F shows a DVS isothermal plot of tartrate Form IV.[000182] FIG. 28G shows a DVS kinetic plot of tartrate Form IV.[000183] FIG. 28H shows exemplary XRPD diffractograms post DVS analysis for tartrate Form IV.[000184] FIG. 28J shows an exemplary XRPD diffractogram of tartrate Form IV.[000185] FIG. 29A shows exemplary XRPD diffractograms from reactive precipitations (without seeding).[000186] FIG. 29B shows exemplary XRPD diffractograms from reactive precipitations (without seeding).[000187] FIG. 30A shows exemplary XRPD diffractograms from reactive precipitations (with seeding).[000188] FIG. 30B shows exemplary XRPD diffractograms from reactive precipitations (with seeding).[000189] FIG. 30C shows exemplary XRPD diffractograms from reactive precipitations (with seeding).[000190] FIG. 31 shows an exemplary XRPD diffractogram of tartrate Form V.[000191] FIG. 32 shows an exemplary XRPD diffractogram of tartrate Form VI.[000192] FIG. 33 shows an exemplary XRPD diffractogram of tartrate Form VII.15IPTS / 200140885.2Attorney Docket No. DCP-147WO[000193] FIG. 34A shows exemplary XRPD diffractograms of the salt screen fumaric acid experiments (post maturation).[000194] FIG. 34B shows exemplary XRPD diffractograms of the salt screen fumaric acid experiments (post 40 °C / 75% RH).[000195] FIG. 34C shows an exemplary TG / DSC thermogram of fumarate Form I from 2- MeTHF.[000196] FIG. 34D shows a1H NMR spectrum of fumarate Form I from 2-MeTHF.[000197] FIG. 35A shows an exemplary XRPD diffractogram of fumarate Form I.[000198] FIG. 35B shows an exemplary TG / DSC thermogram of fumarate Form I.[000199] FIG. 35C shows an exemplary DSC thermogram of the fumarate Form I; 1stheating cycle (20 to 230 °C).[000200] FIG. 3 D shows a DVS isotherm for fumarate Form I.[000201] FIG. 35E shows a DVS kinetic plot for fumarate Form I.[000202] FIG. 35F shows exemplary XRPD diffractograms of fumarate Form I post-DVS.[000203] FIG. 35G shows aJH NMR spectrum fumarate Form I.[000204] FIG. 35H shows exemplary XRPD diffractograms of fumarate Form I poststability.[000205] FIG. 35 J shows exemplary XRPD diffractograms from hydration studies of fumarate Form I.[000206] FIG. 36A shows an exemplary XRPD diffractogram of fumarate Form II.[000207] FIG. 36B shows an exemplary TG / DSC thermogram of fumarate Form II.[000208] FIG. 36C shows an exemplary XRPD diffractogram of fumarate Form III.[000209] FIG. 36D shows an exemplary TG / DSC thermogram of fumarate Form III fromMEK.[000210] FIG. 36E shows aJH NMR spectrum of fumarate Form III from MEK.[000211] FIG. 37A shows exemplary XRPD diffractograms for the salt screen citric acid experiments (post maturation).[000212] FIG. 37B shows exemplary XRPD diffractograms from the salt screen citric acid experiments (post 40 °C / 75% RH).[000213] FIG. 37C shows an exemplary XRPD diffractogram of citrate Form I from acetone (post maturation).16IPTS / 200140885.2Attorney Docket No. DCP-147WO[000214] FIG. 38A shows exemplary XRPD diffractograms of the salt screen DL-mandelic acid experiments (post maturation).[000215] FIG. 38B shows exemplary XRPD diffractograms from the salt screen DL- mandelic acid experiments (post 40 °C / 75% RH).[000216] FIG. 38C shows an exemplary XRPD diffractogram of mandelate Form I from ethanol (post 40 °CZ 75% RH).[000217] FIG. 38D shows an exemplary TG / DSC thermogram of mandelate Form I from ethanol.[000218] FIG. 38E shows 'H NMR spectra of mandelate Form I from ethanol.[000219] FIG. 38F shows an exemplary XRPD diffractogram of mandelate Form II fromDCM (post maturation).[000220] FIG. 39A shows exemplary XRPD diffractograms of the salt screen L-malic acid experiments (post maturation).[000221] FIG. 39B shows exemplary XRPD diffractograms of the salt screen L-malic acid experiments (post 40 °C / 75% RH).[000222] FIG. 40A shows an exemplary XRPD diffractogram of malate Form I.[000223] FIG. 40B shows an exemplary TG / DSC thermogram of malate Form I.[000224] FIG. 40C shows an exemplary DSC thermogram of the malate Form I; 1stheating cycle (20 to 175 °C).[000225] FIG. 40D shows a DVS isotherm for malate Form I.[000226] FIG. 40E shows a DVS kinetic plot for malate Form I.[000227] FIG. 40F shows exemplary XRPD diffractograms of malate Form I post-DVS.[000228] FIG. 40G shows a 'H NMR spectrum malate Form I.[000229] FIG. 41 A shows exemplary XRPD diffractograms of the salt screen DL-lactic acid experiments (post maturation).[000230] FIG. 4 IB shows exemplary XRPD diffractograms of the salt screen DL-lactic acid experiments (post 40 °C / 75% RH).[000231] FIG. 42A shows exemplary XRPD diffractograms from the salt screen benzoic acid experiments (post maturation).[000232] FIG. 42B shows exemplary XRPD diffractograms from the salt screen benzoic acid experiments (post 40 °C / 75% RH).17IPTS / 200140885.2Attorney Docket No. DCP-147WO[000233] FIG. 42C shows an exemplary XRPD diffractogram of benzoate Form I from 2- MeTHF (post 40 °C / 75% RH).[000234] FIG. 42D shows an exemplary TG / DSC thermogram of benzoate Form I from 2- MeTHF.[000235] FIG. 42E shows aJH NMR spectrum of benzoate Form I from 2-MeTHF.[000236] FIG. 42F shows an exemplary XRPD diffractogram of benzoate Form II fromDCM (post maturation).[000237] FIG. 42G shows an exemplary TG / DSC thermogram of benzoate Form II from DCM.[000238] FIG. 42H shows aJH NMR spectrum of benzoate Form II from DCM.[000239] FIG. 43A shows exemplary XRPD diffractograms of the salt screen succinic acid experiments (post maturation).[000240] FIG. 43B shows exemplary XRPD diffractograms from the salt screen succinic acid experiments (post 40 °C / 75% RH).[000241] FIG. 43C shows an exemplary XRPD diffractogram of succinate Form I from 2- MeTHF (post 40 °C / 75% RH).[000242] FIG. 43D shows an exemplary XRPD diffractogram of succinate Form II from ethyl acetate (post 40 °C / 75% RH).[000243] FIG. 43E shows an exemplary TG / DSC thermogram of succinate Form II from MEK.[000244] FIG. 43F shows aJH NMR spectrum of succinate Form II from MEK.[000245] FIG. 44A shows exemplary XRPD diffractograms of the salt screen acetic acid experiments.[000246] FIG. 44B shows exemplary XRPD diffractograms of the salt screen acetic acid experiments (post 40 °C / 75% RH).[000247] FIG. 44C shows an exemplary XRPD diffractogram of acetate Form I from ethyl acetate (post maturation).[000248] FIG. 44D shows an exemplary TG / DSC thermogram of acetate Form I from ethyl acetate.[000249] FIG. 44E shows a1H NMR spectrum of acetate Form I from ethyl acetate.18IPTS / 200140885.2Attorney Docket No. DCP-147WO[000250] FIG. 44F shows an exemplary XRPD diffractogram of acetate Form II from DCM (post maturation).[000251] FIG. 44G shows an exemplary XRPD diffractogram of acetate Form III from DCM (post 40 °C / 75% RH).[000252] FIG. 44H shows an exemplary TG / DSC thermogram of acetate Form III from DCM.[000253] FIG. 44 J shows aNMR spectrum of acetate Form III from DCM.DETAILED DESCRIPTION[000254] The features and other details of the disclosure will now be more particularly described. Certain terms employed in the specification, examples and appended claims are collected here. These definitions should be read in light of the remainder of the disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood.Definitions[000255] Terms used in the singular will also include the plural. For example, “a” means one or more unless indicated otherwise.[000256] All ranges recited herein include the endpoints, including those that recite a range “between” two values. The terms “substantially” and “about” are to be construed as modifying a term or value such that it is not an absolute. This includes, at very least, the degree of expected experimental variance, experimental error, technique variance, technique error and instrument variance, instrumental error for a given technique used to measure a value.[000257] As used herein, “about” includes and describes the value or parameter per se. For example, “about x” includes and describes “x” per se. In some embodiments, the term “about” when used in association with a measurement, or used to modify a value, a unit, a constant, or a range of values, refers to variations of ±10%. “About” in context of XRPD and DSC means ±0.2° at 2-theta for XRPD peaks, ±3 °C for DSC, respectively.[000258] As used herein, the term “adding” does not limit the order, method or how the materials being added are combined, unless indicated otherwise. For instance, “adding X to Y” may also describe “adding Y to X.” Furthermore, “adding X and Y to Z” may also describe the19IPTS / 200140885.2Attorney Docket No. DCP-147WO various other combinations such as “adding X to Y and Z,” “adding X and Z to Y,” “adding Y to X and Z,” “adding Y and Z to X,” and “adding Z to X and Y.”[0002591 As used herein, the term “chemical purity” refers to a measurement of how free a compound is from impurities, which may include other crystalline forms of the compound.[000260] As used herein, the term “by weight” regarding percentage chemical purity refers to the weight of the reference standard (Wstd) times the purity of the reference standard (Pstd), divided by the weight of the working sample (WSmP), times 100.[000261] As used herein, the terms “individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans. The compounds described herein can be administered to a mammal, such as a human, but can also be administered to other mammals such as an animal in need of veterinary treatment, e.g., domestic animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals e.g., rats, mice, guinea pigs, and the like).[000262] As used herein, the term “excipient” refers to a substance that may be beneficial to include in a composition with an active agent. The term “excipient” includes inert substances as well as functional excipients that may result in beneficial properties of the composition. Exemplary excipients include but are not limited to polymers, glidants, sugars, lubricants, salts, buffers, fats, fillers, disintegrating agents, binders, surfactants, high surface area substrates, flavorants, carriers, matrix materials, diluents, and so forth.[000263] As used herein, the terms “pharmaceutically acceptable” or “pharmacologically acceptable” includes molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate. For human administration, preparations should meet sterility, pyrogenicity, and general safety and purity standards as required by FDA standards.[000264] As used herein, the term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” as used herein refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. The compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.20IPTS / 200140885.2Attorney Docket No. DCP-147WO[000265] As used herein, the term “pharmaceutical composition” as used herein refers to a composition comprising at least one compound as disclosed herein formulated together with one or more pharmaceutically acceptable carriers, excipients or diluents.[000266] As used herein, the term “therapeutically effective amount” means the amount of the subject compound that will elicit the biological or medical response of a tissue, system or animal, (e.g., mammal or human) that is being sought by the researcher, veterinarian, medical doctor or other clinician. A compound described herein, e.g., the solid-state form of the compound represented by Formula (I), or a solvate thereof, is administered in therapeutically effective amounts to treat a condition disclosed herein. Alternatively, a therapeutically effective amount of a compound is the quantity required to achieve a desired therapeutic and / or prophylactic effect, such as an amount which results in the prevention of or a decrease in the symptoms associated with the condition.[000267] As used herein and unless otherwise indicated, the terms “treat,” “treating” and “treatment” refer to the alleviation of a disease or disorder and / or at least one of its attendant symptoms, and includes any effect, e.g., lessening, reducing, modulating, or eliminating, that results in the improvement of the condition, disease, disorder and the like.[000268] As used herein and unless otherwise indicated, the terms “prevent,” “preventing” and “prevention” refer to the inhibition of a symptom of a disease or disorder or the disease itself.[000269] As used herein, the term “active agent” means a drug, medicament, pharmaceutical, therapeutic agent, for example, the solid-state form of the compound represented by Formula (I), or a solvate thereof, as described herein.[000270] As used herein, the term “oral formulation,” refers to a composition or medium used to administer a compound as disclosed herein e.g., the solid-state form of the compound represented by Formula (I), or a solvate thereof) to a subject in need thereof by oral administration. Typically, an oral formulation is administered via the mouth, however, “oral formulation” as used herein is intended to cover any substance which is administered to a subject and is absorbed across a membrane, e.g., a mucosal membrane, of the gastrointestinal tract, including, e.g., the mouth, esophagus, stomach, small intestine, large intestine, and colon. In one embodiment, the oral formulation is a solid oral formulation. In one embodiment, the oral formulation is a solid oral formulation administered to a subject in need thereof via the mouth.21IPTS / 200140885.2Attorney Docket No. DCP-147WO[000271] As used herein, the terms “isolated,” “isolating” in reference to solid-state salt forms of the compound represented by Formula (I), or a solvate thereof, corresponds to a solid- state salt form of the compound represented by Formula (I), or a solvate thereof, that is physically separated from the reaction mixture or the slurry.[000272] A reaction mixture may be characterized herein as being at or allowed to come to “room temperature” or “ambient temperature,” often abbreviated as “RT” or “rt.” This means that the temperature of the thing is close to, or the same as, that of the space, e.g., the room or fume hood, in which the thing is located. Typically, room temperature is about 20 °C to about 30 °C, or about 22 °C to about 27 °C, or about 25 °C.[000273] A number of solvents may be employed in a chemical process, e.g., a reaction or crystallization. A suitable solvent may solubilize one or more of the reaction components, or, alternatively, the suitable solvent may facilitate the agitation of a suspension of one or more of the reaction components. A suitable solvent may be combined with one or more additional solvents. Suitable solvents may be characterized according to properties, for example, protic, aprotic, polar, or non-polar. In some embodiments, the suitable solvent may be protic. In some embodiments, the suitable solvent may be aprotic. In some embodiments, the suitable solvent may be polar. In some embodiments, the suitable solvent may be non-polar. In some embodiments, the suitable solvent may be polar protic. In some embodiments, the suitable solvent may be polar aprotic. In some embodiments, the suitable solvent may be non-polar protic. In some embodiments, the suitable solvent may be non-polar aprotic. In some embodiments, suitable solvents may be selected from, but not limited to, water, an ether, an ester, an alcohol, a haloalkane, a ketone, or a mixture thereof. In some embodiments, the suitable solvent may be an alcohol In some embodiments, the alcohol is selected from, but not limited to, methanol, ethanol, propanol, isopropanol, 1-butanol, 2-butanol, i-butyl alcohol, and tert-butanol. In some embodiments, the suitable solvent may be selected from, but not limited to, 2- nitroethanol, 2-fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, 2-m ethoxy ethanol, 2- ethoxy ethanol, di ethylene glycol, 1-, 2-, or 3 -pentanol, neo-pentyl alcohol, t-pentyl alcohol, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, cyclohexanol, benzyl alcohol, phenol, or glycerol. In some embodiments, the suitable solvent may be an ether. In some embodiments, the ether is selected from, but not limited to, tetrahydrofuran, 2- methyltetrahydrofuran, cyclopentyl methyl ether, tert -butyl methyl ether, diethyl ether, 1,4-22IPTS / 200140885.2Attorney Docket No. DCP-147WO dioxane, glyme, and diglyme. Tn some embodiments, the suitable solvent may be an ester. Tn some embodiments, the ester is selected from, but not limited to, ethyl acetate, and isopropyl acetate. In some embodiments, the suitable solvent may be a ketone. In some embodiments, the ketone is selected from, but not limited to, acetone, methyl ethyl ketone, methyl isobutyl ketone, and hexachloroacetone. In some embodiments, the suitable solvent may be a haloalkane. In some embodiments, the haloalkane is selected from, but not limited to, dichloromethane, 1,2- di chloroethane, 1,2-di chloroethene, and chloroform. In some embodiments, the suitable solvent may be a nitrile. In some embodiments, the nitrile is selected from, but not limited to, acetonitrile and propionitrile. In some embodiments, the suitable solvent may be an alkane. In some embodiments, the alkane is selected from, but not limited to, heptane, hexane, pentane, and cyclohexane. In some embodiments, the suitable solvent may be an amide. In some embodiments, the amide is selected from, but not limited to, Ar,A -di methyl form am ide, NJV- dimethylacetamide, .V-m ethyl pyrrolidinone, and formamide. In some embodiments, the suitable solvent may be an aromatic compound. In some embodiments, the aromatic compound is selected from, but not limited to, benzene, toluene, ethylbenzene, pyridine and xylene. In some embodiments, the suitable solvent may be water. In some embodiments, the suitable solvent may be ammonia or acetic acid. In some embodiments, the suitable solvent may be dimethyl sulfoxide. In some embodiments, the solvent may be a mixture of a protic and / or an aprotic solvent. In some embodiments, the solvent may be a mixture of a protic and / or aprotic solvent and water. At least the aforementioned solvents provide a solvent means for preparing a solid-state form of the compound of Formula (I). At least the aforementioned solvents provide a solvent means for preparing a crystalline solid-state form of the compound of Formula (I). At least the aforementioned solvents provide a solvent means for preparing an amorphous solid-state form of the compound of Formula (I). At least the aforementioned solvents provide a solvent means for preparing a solid-state salt form of the compound of Formula (I). At least the aforementioned solvents provide a solvent means for preparing an amorphous solid-state salt form of the compound of Formula (I). At least the aforementioned solvents provide a solvent means for preparing a crystalline solid-state salt form of the compound of Formula (I).[000274] The amount of solvent employed in a chemical process, e.g., a reaction or crystallization, may be referred to herein as a number of “volumes” or “vol” or “V.” For example, a material may be referred to as being suspended in 10 volumes (or 10 vol or 10V) of a23IPTS / 200140885.2Attorney Docket No. DCP-147WO solvent. Tn this context, this expression would be understood to mean milliliters of the solvent per gram of the material being suspended, such that suspending 5 grams of a material in 10 volumes of a solvent means that the solvent is used in an amount of 10 milliliters (mL) of the solvent per gram of the material that is being suspended or, in this example, 50 mL of the solvent. In another context, the term “N / N” may be used to indicate the number of volumes of a solvent that are added to a liquid mixture based on the volume of that mixture. For example, adding solvent X (1.5 v / v) to a 100 mL reaction mixture would indicate that 150 mL of solvent X was added.[000275] The abbreviation “MEK” is used herein. It will be understood that the abbreviation “MEK” refers to methyl ethyl ketone or to mitogen-activated protein kinase, depending on the context.[000276] A process or step may be referred to herein as being carried out “overnight.” This refers to a time interval, e.g., for the process or step, that spans the time during the night, when that process or step may not be actively observed. This time interval is about 8 to about 24 hours, or about 10-18 hours, typically about 16 hours.[000277] As used herein, the term “reduced pressure” refers to a pressure that is less than atmospheric pressure. For example, a reduced pressure employed, for example in the context of drying conditions, is about 10 mbar to about 50 mbar, preferably 30-50 mbar.[000278] As used herein, and unless indicated otherwise, the term “wet cake” refers to a crystalline form or solid that was not dried using any conventional techniques to remove residual solvent. Examples of such conventional techniques can be, but are not limited to, evaporation, vacuum drying, oven drying, drying under nitrogen flow, etc.[000279] In general, a solid-state form (e.g., solid-state salts forms described herein), such as a crystal form or amorphous form, may be referred to herein as being characterized by graphical data “as depicted in,” “as shown in,” “substantially as depicted in,” or substantially as shown in.” This will be understood to describe the solid-state salt form of the compound represented by Formula (I), or a solvate thereof, characterized with the graphical data having such small variations Such data include, for example, powder X-ray diffractograms and solid- state NMR spectra. As is well-known in the art, the graphical data potentially provides additional technical information to further define the respective solid-state form (a so-called “fingerprint”) which cannot necessarily be described by reference to numerical values or peak positions alone.24IPTS / 200140885.2Attorney Docket No. DCP-147WOSuch graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to certain factors such as, but not limited to, variations in instrument response and variations in sample concentration and purity.[000280] A crystal is composed of atoms periodically arranged in a 3D space (i.e., a repeating pattern) while in amorphous materials atoms are randomly distributed in the 3D space (i.e., no long-range order). As a result, the X-ray diffractogram of a crystalline material will display narrow peaks of high intensity due the fact that the x-rays are scattered in only certain directions (due to the periodic arrangement of the atoms). In contrast, the X-ray diffractogram of an amorphous material generally displays broad peaks (halo pattern) of low intensity because the x-rays are scattered in many different directions leading to large bumps distributed over a wide range (2 Theta).[000281] A crystal form of the compound represented by Formula (I), or a salt or solvate thereof, referred to herein as being characterized by graphical data “as depicted in” or “as substantially depicted in” a Figure will thus be understood to include any crystal forms of the compound represented by Formula (I), or a salt or solvate thereof, characterized with the graphical data having such small variations in comparison with the Figure.[000282] In addition, where a reference is made to a Figure, it is permissible to, and this document includes and contemplates, the selection of any number of data points illustrated in the figure that uniquely define that crystalline form, within any associated and recited margin of error, for purposes of identification.[000283] As used herein, the term “stability” generally refers to the tendency of a material to resist change or decomposition in its natural environment, or when exposed to air, heat, light, humidity, pressure, or other natural conditions, or due to internal reaction. In some embodiments, the material is exposed to heat (e.g., about 30 °C, about 40 °C, about 50 °C, about 60 °C, about 70 °C, about 80 °C) in a stability determination. In some embodiments, the material is exposed to humidity (e.g., 75% RH) in a stability determination. In some embodiments, the material is exposed to heat and humidity (e.g., about 40 °C and about 75% RH) in a stability determination. [000284] As used herein and unless otherwise indicated, the terms “polymorph” and “polymorphic form” refer to solid crystalline forms of a compound or complex. In some embodiments, polymorphic forms include, but are not limited to, crystalline, amorphous, solvate, or hydrate. Different polymorphs of the same compound can exhibit different and / or improved25IPTS / 200140885.2Attorney Docket No. DCP-147WO physical, chemical and / or spectroscopic properties. Different physical properties include, but are not limited to stability (e.g., to heat or light), compressibility and density (important in formulation and product manufacturing), and dissolution rates (which can affect bioavailability). [000285] As used herein, a polymorphic form may be described by reference to patterns, spectra, or other graphical data as “substantially” shown or depicted in a figure, or by one or more data points. It will be appreciated that patterns, spectra, and other graphical data can be shifted in their positions, relative intensities, or other values due to a number of factors . For example, in the crystallographic and powder X-ray diffraction arts, shifts in peak positions or the relative intensities of one or more peaks of a pattern can occur because of, without limitation, the equipment used, the sample preparation protocol, preferred packing and orientations, the radiation source, operator error, method and length of data collection, or the like.[000286] The occurrence of different polymorphs is possible for some compounds. A single compound may give rise to a variety of solids having distinct physical properties, such as X-ray diffraction patterns, infrared absorption spectra, and NMR spectra. This variation in solid forms may be significant and may result in differences with respect to bioavailability, stability, and other differences for formulated pharmaceutical products.[000287] While the existence and possible numbers of polymorphic forms for a given pharmaceutical compound cannot be predicted, different polymorphs can possess different properties such as stability, solubility, melting point, or compressibility. As a result, new forms of a pharmaceutically useful compound may provide an opportunity to improve its characteristics, and ultimately its performance. Further, discovery of additional polymorphic forms, including solvate polymorphs, may help in the identification of the polymorphic content of a batch of an active pharmaceutical ingredient. For example, in some cases, different polymorphs of the same drug can exhibit very different solubility and different dissolution rates. [000288] Differences in stability can result from changes in chemical reactivity (e.g., differential oxidation, such that a dosage form discolors more rapidly when comprised of one polymorph than when comprised of another polymorph) or mechanical characteristics (e.g, tablets crumble on storage as a kinetically favored polymorph converts to thermodynamically more stable polymorph) or both (e.g., tablets of one polymorph are more susceptible to breakdown at high humidity). Different physical properties of polymorphs can affect their processing. For example, one polymorph might be more likely to form solvates or might be more26IPTS / 200140885.2Attorney Docket No. DCP-147WO difficult to filter or wash free of impurities than another due to, for example, the shape or size distribution of particles of it.[0002891 Polymorphs of a molecule can be obtained by a number of methods. Such methods include, but are not limited to, melt recrystallization, melt cooling, solvent recrystallization, desolvation, rapid evaporation, rapid cooling, slow cooling, vapor diffusion and sublimation. Polymorphs can be detected, identified, classified and characterized using well- known techniques such as, but not limited to, differential scanning calorimetry (DSC), thermogravimetry (TG), X-ray powder diffractometry (XRPD), single crystal X-ray diffractometry, vibrational spectroscopy, solution calorimetry, solid-state nuclear magnetic resonance (NMR), infrared (IR) spectroscopy, Raman spectroscopy, hot stage optical microscopy, scanning electron microscopy (SEM), electron crystallography and quantitative analysis, particle size analysis (PSA), surface area analysis, solubility, and rate of dissolution.[000290] Different solid-state forms can be characterized by scattering techniques, e.g., x- ray powder diffraction (XRPD) pattern, by spectroscopic methods, e.g., infrared absorption fingerprint, Raman absorption fingerprint, nuclear magnetic resonance (e.g., NMR, solid-state NMR) spectroscopy (e.g., 'H,13C,19F), and by thermal techniques, e.g., differential scanning calorimetry (DSC) or thermogravimetric analysis (TGA). Described herein are polymorphs (solid-state forms) of a salt of the compound represented by Formula (I). These solid-state forms and their distinct crystal structures and physical properties are characterized by TGA, DSC (measurement of melting point and thermal behavior), XRPD, and NMR such as proton NMR spectrum ('H NMR).[000291] As used herein to refer to the spectra or data presented in graphical form (e.g., XRPD, IR, Raman and NMR spectra), and unless otherwise indicated, the term “peak” refers to a peak or other special feature that not attributable to background noise.[000292] Generally, a diffraction angle (20, “2 theta”) in X-ray powder diffractometry may have a variation in the range of ± 0.2°. Therefore, the aforementioned diffraction angle values should be understood as including values in the range of about ± 0.2°. Accordingly, the solid- state forms described here includes not only crystals whose peak diffraction angles in powder X- ray diffractometry completely coincide with each other, but also crystals whose peak diffraction angles coincide with each other with an error of about ±.0.2°. Therefore, in the present specification, the phrase “having a diffraction peak at a diffraction angle (20 ± 0.2°) of 8.0°”27IPTS / 200140885.2Attorney Docket No. DCP-147WO means “having a diffraction peak at a diffraction angle (20) of 7.8° to 8.2°.” In some embodiments, the diffraction angle may have a variation in the range of ± 0.1°. Therefore, in the present specification, the phrase “having a diffraction peak at a diffraction angle (29 ± 0.1°) of 8.0°” means “having a diffraction peak at a diffraction angle (20) of 7.9° to 8.1°. ’’Although the intensities of peaks in the x-ray powder diffraction patterns of different batches of a compound may vary slightly, the peak locations are characteristic for a specific polymorphic form. In some embodiments, the XRPD peak pattern may vary due to measurement errors, differing measurement conditions, and may display variations in peak intensity ( / .e., identical order of intensity of peaks are not required). Alternatively, the term “about” means within an acceptable standard error of the mean. The relative intensities of the XRPD peaks can vary depending on the sample preparation technique, crystal size distribution, various filters used, the sample mounting procedure, and the particular instrument employed. Moreover, instrument variation and other factors can affect the 2-theta values. Therefore, the term “substantially” in the context of XRPD is meant to encompass that any peak assignment can vary by plus or minus about 0.2°. In some embodiments, any peak assignment can vary by plus or minus about 0.1°. Moreover, new peaks may be observed, or existing peaks may disappear, depending on the type of the machine or the settings (for example, whether a Ni filter is used or not).[000293] Generally, a DSC thermogram may have a variation in the range of ± 3 °C. Therefore, the temperature values should be understood as including values in the range of ± 3 °C.[000294] In general, provided herein are solid-state salt forms of the compound represented by Formula (I), or a solvate thereof, that are substantially free of any other solid-state forms whether as individual forms or mixtures of other forms, unless indicated otherwise. For example, hydrobromide Form II of the compound represented by Formula (I) will be substantially free of other forms of compound of Formula (I), or a solvate thereof, which may include other solid- state forms (e.g., hydrobromide Form I) of the compound represented by Formula (I), or solid- state forms the compound represented by Formula (I) as free base, or a solvate thereof, or mixtures thereof. As used herein, “substantially free of any solid-state forms” means that the solid-state salt form of the compound represented by Formula (I), or a solvate thereof, contains about 20% or less, about 10% or less, about 5% or less, about 2% or less, or about 1% or less, of any other solid-state form of the compound represented by Formula (I), or a solvate thereof, as28IPTS / 200140885.2Attorney Docket No. DCP-147WO measured, for example, by XRPD. In some embodiments, the solid-state salt form of the compound represented by Formula (I), or a solvate thereof, contains less than about 20%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% of any other solid-state forms of the compound represented by Formula (I), or a solvate thereof, as measured, for example, by XRPD. Thus, a solid-state salt form of the compound represented by Formula (I), or a solvate thereof, described herein as substantially free of any other solid-state forms would be understood to contain greater than 80% (w / w), greater than 90% (w / w), greater than 95% (w / w), greater than 98% (w / w), or greater than 99% (w / w) of the said solid-state salt forms of the compound represented by Formula (I), or a solvate thereof. Accordingly, in some embodiments, the described solid-state salt forms of the compound represented by Formula (I), or a solvate thereof, may contain from 1% to 20% (w / w), from 5% to 20% (w / w), or from 5% to 10% (w / w) of one or more other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000295] As used herein, “substantially free” means that the solid-state forms of the present disclosure contain 20% (w / w) or less of any other solid-state forms, or, alternatively, of a specific polymorph of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the solid-state forms of the present disclosure contain 10% (w / w) or less, 5% (w / w) or less, 2% (w / w), 1% (w / w) or less of any other solid-state forms, or specific polymorphs of the compound represented by Formula (I), or a solvate thereof. In other embodiments, solid- state forms of the compound represented by Formula (I), or a solvate thereof, of the present disclosure contain from 1% to 20% (w / w), from 5% to 20% (w / w), or from 5% to 10% (w / w) of other solid-state forms, or of a specific polymorph of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the any other solid-state forms, or specific polymorphs of the compound represented by Formula (I), or a solvate thereof includes any amount of solid-state material which may be present as to be undetectable by conventional means.[000296] As used herein and unless otherwise indicated, the term “substantially pure” when used to describe a polymorph of a compound means a solid form of the compound that comprises that polymorph and is substantially free of other polymorphs of the compound or other impurities. For example, hydrobromide Form II of the compound represented by Formula (I) will be substantially pure while being substantially free of other forms of compound of Formula (I),29IPTS / 200140885.2Attorney Docket No. DCP-147WO or a solvate thereof, which may be other solid-state forms (e.g., hydrobromide Form T) of the compound represented by Formula (I), or the compound represented by Formula (I) as free base, or a solvate thereof, or mixtures thereof. A representative substantially pure polymorph comprises greater than about 80% by weight of one polymorphic form of the compound and less than about 20% by weight of other polymorphic forms of the compound or other impurities. In some embodiments, a representative substantially pure polymorph comprises greater than about 90% by weight of one polymorphic form of the compound and less than about 10% by weight of the other polymorphic forms of the compound or other impurities. In some embodiments, a representative substantially pure polymorph comprises greater than about 95% by weight of one polymorphic form of the compound and less than about 5% by weight of the other polymorphic forms of the compound or other impurities. In some embodiments, a representative substantially pure polymorph comprises greater than about 97% by weight of one polymorphic form of the compound and less than about 3% by weight of the other polymorphic forms of the compound or other impurities. In some embodiments, a representative substantially pure polymorph comprises greater than about 98% by weight of one polymorphic form of the compound and less than about 2% by weight of the other polymorphic forms of the compound or other impurities. In some embodiments, a representative substantially pure polymorph comprises greater than about 99% by weight of one polymorphic form of the compound and less than about 1% by weight of the other polymorphic forms of the compound or other impurities. In some embodiments, a representative substantially pure polymorph comprises greater than about 99.5% by weight of one polymorphic form of the compound and less than about 0.5% by weight of any other solid- state forms of the compound or other impurities. In some embodiments, a representative substantially pure polymorph comprises greater than about 99.8% by weight of one polymorphic form of the compound and less than about 0.2% by weight of any other solid-state forms of the compound or other impurities. In some embodiments, a representative substantially pure polymorph comprises greater than about 99.9% by weight of one polymorphic form of the compound and less than about 0.1% by weight of any other solid-state forms of the compound or other impurities. In some embodiments, a representative substantially pure polymorph comprises greater than about 99.95% by weight of one polymorphic form of the compound and less than about 0.05% by weight of any other solid-state forms of the compound or other impurities. In some embodiments, a representative substantially pure polymorph comprises one polymorphic30IPTS / 200140885.2Attorney Docket No. DCP-147WO form of the compound and any other solid-state forms of the compound or other impurities are undetectable.[0002971 Insome embodiments, a crystalline or amorphous form that is “pure,” i.e., substantially free of other crystalline or amorphous forms or other impurities, contains less than about 10 percent by weight of one or more other crystalline or amorphous form or other impurities. In some embodiments, a crystalline or amorphous form that is “pure,”, contains less than about 5 percent by weight of one or more other crystalline or amorphous form or other impurities. In some embodiments, a crystalline or amorphous form that is “pure,” contains less than about 3 percent by weight of one or more other crystalline or amorphous form or other impurities. In some embodiments, a crystalline or amorphous form that is “pure,” contains less than about 1 percent by weight of one or more other crystalline or amorphous form or other impurities.[000298] The content of solid-state forms is typically measured by any suitable method , for example XRPD, solid-state NMR, IR, Raman, or DSC.[000299] Crystalline and partially crystalline solid forms may be prepared by a variety of methods including, but not limited to, for example, crystallization or recrystallization from a suitable solvent mixture; sublimation; growth from a melt; solid-state transformation from another phase; crystallization from a supercritical fluid; antisolvent addition; slurrying at various temperatures (e.g, at room temperature, at 10 °C, at 15 °C, at 40 °C, at 50 °C, at 70 °C); solid vapor diffusion; liquid vapor diffusion; evaporation; slow cooling, polymer induced crystallization; milling; spray freezing; spray congealing; lyophilization; and humidity induced crystallization. Techniques for crystallization or recrystallization of crystalline and partially crystalline solid forms of a solvent mixture include, but are not limited to, for example, evaporation of the solvent; decreasing the temperature of the solvent mixture; crystal seeding of a supersaturated solvent mixture of the compound thereof; crystal seeding a supersaturated solvent mixture of the compound thereof; freeze drying the solvent mixture; temperature cycling (e.g, cycling through two temperature extremes, typically at relatively high rates of change); and adding anti-solvents (countersolvents) to the solvent mixture. As used herein, the term “antisolvent” refers to a liquid that, when combined with a solution of the compound represented by Formula (I), or a solvate thereof, reduces solubility of the compound represented by Formula (I), or a solvate thereof, in the solution, causing crystallization or precipitation in some instances31IPTS / 200140885.2Attorney Docket No. DCP-147WO spontaneously, and in other instances with additional steps, such as seeding, cooling, scratching and / or concentrating. Crystals of drugs, including polymorphs, methods of preparation, and characterization of drug crystals, are discussed in Solid-State Chemistry of Drugs, S. R. Bym, R. R. Pfeiffer, and J. G. Stowell, 2nd Edition, SSCI, West Lafayette, Ind. (1999). In a crystallization technique in which solvent is employed, the solvent(s) are typically chosen based on one or more factors including, but not limited to, for example, solubility of the compound; crystallization technique utilized; and vapor pressure of the solvent. Combinations of solvents may be employed. For example, the compound may be solubilized in a first solvent to afford a solution to which anti solvent is then added to decrease the solubility of the compound represented by Formula (I), or a solvate thereof, in the solution and precipitate the formation of crystals. An antisolvent is a solvent in which a compound has low solubility. In one method that can be used in preparing crystals, a compound can be suspended and / or stirred in a suitable solvent to afford a slurry, which may be heated to promote dissolution. A cooled crystallization mixture may be filtered under vacuum and the isolated solid product washed with a suitable solvent, such as, for example, cold recrystallization solvent. After being washed, the product may be dried under a nitrogen purge to afford the desired solid form. After being washed, the product may be dried under vacuum to afford the desired solid form.[000300] The term “solvate” as used herein refers to a physical association of the compound of Formula (I) with solvent molecule(s). This physical association may involve varying degrees of ionic and covalent bonding including, but not limited to, hydrogen bonding. In certain instances, the solvate will be capable of isolation. “Solvate” encompasses both solution-phase and isolatable solvates. A “hydrate” as used herein is a solvate in which the solvent molecule(s) are water molecules (H2O). In certain instances, the hydrate form is a hemihydrate form, a monohydrate form, a sesquihydrate form, a dihydrate form, a trihydrate form, a tetrahydrate form, a pentahydrate form, a hexahydrate form, a heptahydrate form, an octahydrate form, a nonahydrate form, or a decahydrate form.[000301] As used herein, a crystal form that is “essentially free” of water and / or solvent in the crystal lattice has a quantity of water and / or solvent in the crystal lattice which is, in some embodiments, approximately near the limit of detection, in some other embodiments approximately at the limit of detection, and in some other embodiments approximately below the limit of detection for solvent and / or water in the crystal lattice, when measured using a32IPTS / 200140885.2Attorney Docket No. DCP-147WO conventional solid-state analytical technique. In some embodiments, the solid-state analytical technique used to determine the quantity of water and / or solvent in the crystal lattice is thermogravimetric analysis. In some embodiments, the solid-state analytical technique used to determine the quantity of water and / or solvent in the crystal lattice is Karl Fischer analysis. In some embodiments, a crystal form which is “essentially free” of water and / or solvent in the crystal lattice has a water and / or solvent content which is less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1%, less than about 0.9%, less than about 0.8%, less than about 0.7%, less than about 0.6%, less than about 0.5%, less than about 0.4%, less than about 0.3%, less than about 0.2%, less than about 0.1%, less than about 0.05%, or less than about 0.01%, of the total weight of the crystal form.Salt forms of the compound of Formula (I)[000302] The present disclosure encompasses salt forms of the compound represented by Formula (I):[000303] In some embodiments, the salt is selected from the group consisting of hydrobromide, hydrochloride, napadisylate, sulfate, edisylate, cyclamate, tosylate, thiocyanate, mesylate, napsylate, besylate, oxalate, aspartate, maleate, pamoate, malonate, gentisate, salicylate, tartrate, fumarate, mandelate, malate, benzoate, succinate, acetate, phosphate, ethanesulfonate, glutarate, citrate, and lactate. In some embodiments, the salt is selected from the group consisting of hydrobromide, hydrochloride, napadisylate, sulfate, edisylate, cyclamate, tosylate, thiocyanate, mesylate, napsylate, besylate, oxalate, aspartate, maleate, pamoate, malonate, gentisate, salicylate, tartrate, fumarate, mandelate, malate, benzoate, succinate, and acetate. In some embodiments, the salt is selected from the group consisting of hydrobromide, napadisylate, tartrate, napsylate, malate, gentisate, fumarate, and pamoate. In some embodiments, the salt is selected from hydrobromide, malate, fumarate, and tartrate.33IPTS / 200140885.2Attorney Docket No. DCP-147WO[000304] In some embodiments, salts of the disclosure can be prepared by any suitable method for the preparation of acid addition salts. For example, a free base form of the compound represented by Formula (I) can be combined with the desired acid in a solvent or solvent mixture or in a melt. In some embodiments, the acid salt is selected from the group consisting of hydrobromide, hydrochloride, napadisylate, sulfate, edisylate, cyclamate, tosylate, thiocyanate, mesylate, napsylate, besylate, oxalate, aspartate, maleate, pamoate, malonate, gentisate, salicylate, tartrate, fumarate, mandelate, malate, benzoate, succinate, acetate, phosphate, ethanesulfonate, glutarate, citrate, lactate, bicarbonate, bitartrate, camsylate, carbonate, decanoate, edetate, gluceptate, gluconate, glutamate, glycolate, hexanoate , hydroxynaphthoate, hydroiodide, isethionate, lactobionate, methyl sulfate, mucate, nitrate, octanoate, oleate, pantothenate, polygalacturonate, propionate, stearate, 4-methylbicyclo[2.2.2]oct-2-ene- carboxylate, glucoheptonate, 4.4’-methylenebis(3-hydroxy-2- ene-1 -carboxylate), 3- phenylpropionate, trimethylacetate, tertiary butylacetate, lauryl sulfate, hydroxynaphthoate, diphosphate, heptanoate, cyclopentanepropionate, pyruvate, cinnamate, o-(4- hydroxybenzoyl)benzoate p-chlorbenzenesulfonate, 1,2, -ethanedisulfonate, and 2- hydroxyethanesulfonate. Alternatively, an acid addition salt of the compound represented by Formula (I) can be converted to a different acid addition salt by anion exchange. Salts of the disclosure which are prepared in a solvent system can be isolated, for example, by precipitation from the solvent or the solvent mixture. Precipitation and / or crystallization can be induced, for example, by evaporation, reduction of temperature, addition of anti-solvent, or combinations thereof. In some embodiments, the anti-solvent is tert-butyl methyl ether.[000305] In some embodiments, the acid may be added to the mixture of the compound represented by Formula (I) and a suitable solvent in any suitable form. For example, the acid may be added in solid form or as a solution or a suspension in a suitable solvent or as a gas. The suitable solvent or solvent mixture may be the same suitable solvent or solvent mixture as that which is combined with the compound represented by Formula (I) or may be a different solvent or different solvent mixture. In some embodiments, the acid is added in solid form. In some embodiments, the acid is combined with a suitable solvent prior to adding to the compound represented by Formula (I). In some embodiments, the acid is added as a solution in a suitable solvent or solvent mixture. In some embodiments, the acid is added as a gas.34IPTS / 200140885.2Attorney Docket No. DCP-147WO[000306] In some embodiments, the salt forming reactions described herein can be carried out at appropriate temperatures. Reaction temperatures will depend on, for example, the melting and boiling points of the reagents and solvent, if present; the thermodynamics of the reaction (e.g., vigorously exothermic reactions may need to be carried out at reduced temperatures); and the kinetics of the reaction (e.g., a high activation energy barrier may need elevated temperatures). In some embodiments, the salt forming reaction is carried out at ambient temperature. In some embodiments, temperature-cycling is employed. In some embodiments, the temperature-cycling is between ambient temperature and about 50 °C. In some embodiments, the temperature-cycling is between ambient temperature and about 40 °C. In some embodiments, the temperature-cycling is between ambient temperature and about 30 °C.[000307] In some embodiments, the salt form of the compound is substantially pure. In some embodiments, the salt form of the compound is essentially free of solvents.[000308] In some embodiments, the salt form of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the salt form of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the salt form of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the salt form of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the salt form of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the salt form of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the salt form of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the salt form of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the salt form of the compound has a chemical purity of greater than 99% by weight.[000309] In some embodiments, the salt form of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the salt form of the compound has no more than about 10 mol% of other salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the salt form of the compound has no more than about 9 mol% of other salt forms of the compound represented by35IPTS / 200140885.2Attorney Docket No. DCP-147WOFormula (I), or a solvate thereof. In some embodiments, the salt form of the compound has no more than about 8 mol% of other salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the salt form of the compound has no more than about 7 mol% of other salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the salt form of the compound has no more than about 6 mol% of other salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the salt form of the compound has no more than about 5 mol% of other salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the salt form of the compound has no more than about 4 mol% of other salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the salt form of the compound has no more than about 3 mol% of other salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the salt form of the compound has no more than about 2 mol% of other salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the salt form of the compound has no more than about 1 mol% of other salt forms of the compound represented by Formula (I), or a solvate thereof. [000310] Also provided herein are pharmaceutical compositions comprising the salt form of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier. [000311] In some embodiments, the salt form is present in the composition in an amount of at least about 80% by weight. In some embodiments, the salt form is present in the composition in an amount of at least about 85% by weight. In some embodiments, the salt form is present in the composition in an amount of at least about 90% by weight. In some embodiments, the salt form is present in the composition in an amount of at least about 95% by weight. In some embodiments, the salt form is present in the composition in an amount of at least about 96% by weight. In some embodiments, the salt form is present in the composition in an amount of at least about 97% by weight. In some embodiments, the salt form is present in the composition in an amount of at least about 98% by weight. In some embodiments, the salt form is present in the composition in an amount of at least about 99% by weight.[000312] In some embodiments, provided herein is a pharmaceutical composition comprising the salt form of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the36IPTS / 200140885.2Attorney Docket No. DCP-147WO salt form of the compound represented by Formula (I), which is in the form of a tablet. In some embodiments, the composition is for oral administration.[0003131 Also provided herein, in some embodiments, are pharmaceutical compositions consisting essentially of the salt form described herein, or combinations thereof, and a pharmaceutically acceptable carrier. In some embodiments, the composition is for oral administration.Solid-state salt forms of the compound of Formula (I)[000314] The present disclosure encompasses solid-state salt forms of the compound represented by Formula (I):or a solvate thereof.[000315] In some embodiments, the solid-state salt form is amorphous.[000316] In some embodiments, the amorphous solid-state salt form of the compound ofFormula (I) is in a hydrate form (the compound of Formula ( nFhO). For example, the hydrate form is a hemihydrate form, a monohydrate form, a sesquihydrate form, a dihydrate form, a trihydrate form, a tetrahydrate form, a pentahydrate form, a hexahydrate form, a heptahydrate form, an octahydrate form, a nonahydrate form, or a decahydrate form. In some embodiments, the hydrate form is a hemihydrate form, a monohydrate form, a sesquihydrate form, a dihydrate form, a trihydrate form, or a tetrahydrate form.[000317] In some embodiments, the salt is selected from the group consisting of hydrobromide, hydrochloride, napadisylate, sulfate, edisylate, cyclamate, tosylate, thiocyanate, mesylate, napsylate, besylate, oxalate, aspartate, maleate, pamoate, malonate, gentisate, salicylate, tartrate, fumarate, mandelate, malate, benzoate, succinate, acetate, phosphate, ethanesulfonate, glutarate, citrate, and lactate. In some embodiments, the salt is selected from the group consisting of hydrobromide, hydrochloride, napadisylate, sulfate, edisylate, cyclamate,37IPTS / 200140885.2Attorney Docket No. DCP-147WO tosylate, thiocyanate, mesylate, napsylate, besylate, oxalate, aspartate, maleate, pamoate, malonate, gentisate, salicylate, tartrate, fumarate, mandelate, malate, benzoate, succinate, and acetate. In some embodiments, the salt is selected from the group consisting of hydrobromide, napadisylate, tartrate, napsylate, malate, gentisate, fumarate, and pamoate. In some embodiments, the salt is selected from hydrobromide, malate, fumarate, and tartrate.[000318] In some embodiments, the amorphous solid-state salt form of the compound is substantially pure. In some embodiments, the amorphous solid-state salt form of the compound is essentially free of solvents.[000319] In some embodiments, the amorphous solid-state salt form of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the amorphous solid-state salt form of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the amorphous solid-state salt form of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the amorphous solid-state salt form of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the amorphous solid-state salt form of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the amorphous solid-state salt form of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the amorphous solid-state salt form of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the amorphous solid-state salt form of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the amorphous solid-state salt form of the compound has a chemical purity of greater than 99% by weight.[000320] In some embodiments, the amorphous solid-state salt form of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state salt form of the compound has no more than about 10 mol% of other solid-state salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state salt form of the compound has no more than about 9 mol% of other solid-state salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state salt form of38IPTS / 200140885.2Attorney Docket No. DCP-147WO the compound has no more than about 8 mol% of other solid-state salt forms of the compound represented by Formula (I), or a solvate thereof In some embodiments, the amorphous solid- state salt form of the compound has no more than about 7 mol% of other solid-state salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state salt form of the compound has no more than about 6 mol% of other solid- state salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state salt form of the compound has no more than about 5 mol% of other solid-state salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state salt form of the compound has no more than about 4 mol% of other solid-state salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state salt form of the compound has no more than about 3 mol% of other solid-state salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state salt form of the compound has no more than about 2 mol% of other solid-state salt forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state salt form of the compound has no more than about 1 mol% of other solid-state salt forms of the compound represented by Formula (I), or a solvate thereof.[000321] Also provided herein are pharmaceutical compositions comprising the amorphous solid-state salt form of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000322] In some embodiments, the amorphous solid-state salt form is present in the composition in an amount of at least about 80% by weight. In some embodiments, the amorphous solid-state salt form is present in the composition in an amount of at least about 85% by weight. In some embodiments, the amorphous solid-state salt form is present in the composition in an amount of at least about 90% by weight. In some embodiments, the amorphous solid-state salt form is present in the composition in an amount of at least about 95% by weight. In some embodiments, the amorphous solid-state salt form is present in the composition in an amount of at least about 96% by weight. In some embodiments, the amorphous solid-state salt form is present in the composition in an amount of at least about 97% by weight. In some embodiments, the amorphous solid-state salt form is present in the composition in an amount of at least about 98% by weight. In some embodiments, the39IPTS / 200140885.2Attorney Docket No. DCP-147WO amorphous solid-state salt form is present in the composition in an amount of at least about 99% by weight.[0003231 Insome embodiments, provided herein is a pharmaceutical composition comprising the amorphous solid-state salt form of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the amorphous solid-state salt form of the compound represented by Formula (I), which is in the form of a tablet. In some embodiments, the composition is for oral administration.[000324] Also provided herein, in some embodiments, are pharmaceutical compositions consisting essentially of the amorphous solid-state salt form described herein, or combinations thereof, and a pharmaceutically acceptable carrier. In some embodiments, the composition is for oral administration.[000325] In some embodiments, provided herein are crystalline solid-state salt forms of the compound represented by Formula (I):or a solvate thereof.[000326] In some embodiments, the crystalline solid-state salt form of the compound of Formula (I) is in a hydrate form (the compound of Formula (I)*nH2O). For example, the hydrate form is a hemihydrate form, a monohydrate form, a sesquihydrate form, a dihydrate form, a trihydrate form, a tetrahydrate form, a pentahydrate form, a hexahydrate form, a heptahydrate form, an octahydrate form, a nonahydrate form, or a decahydrate form. In some embodiments, the hydrate form is a hemihydrate form, a monohydrate form, a sesquihydrate form, a dihydrate form, a trihydrate form, or a tetrahydrate form.[000327] In some embodiments, the salt is selected from the group consisting of hydrobromide, hydrochloride, napadisylate, sulfate, edisylate, cyclamate, tosylate, thiocyanate,40IPTS / 200140885.2Attorney Docket No. DCP-147WO mesylate, napsylate, besylate, oxalate, aspartate, maleate, pamoate, malonate, gentisate, salicylate, tartrate, fumarate, mandelate, malate, benzoate, succinate, acetate, phosphate, ethanesulfonate, glutarate, citrate, and lactate. In some embodiments, the salt is selected from the group consisting of hydrobromide, hydrochloride, napadisylate, sulfate, edisylate, cyclamate, tosylate, thiocyanate, mesylate, napsylate, besylate, oxalate, aspartate, maleate, pamoate, malonate, gentisate, salicylate, tartrate, fumarate, mandelate, malate, benzoate, succinate, and acetate. In some embodiments, the salt is selected from the group consisting of hydrobromide, napadisylate, tartrate, napsylate, malate, gentisate, fumarate, and pamoate. In some embodiments, the salt is selected from hydrobromide, malate, fumarate, and tartrate.[000328] In some embodiments, the crystalline solid-state salt form of the compound is substantially pure. In some embodiments, the crystalline solid-state salt form of the compound is essentially free of solvents.[000329] In some embodiments, the crystalline solid-state salt form of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the crystalline solid-state salt form of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state salt form of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state salt form of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the crystalline solid-state salt form of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the crystalline solid-state salt form of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the crystalline solid-state salt form of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the crystalline solid-state salt form of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the crystalline solid-state salt form of the compound has a chemical purity of greater than 99% by weight.[000330] In some embodiments, the crystalline solid-state salt form of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state salt form of the compound has no more41IPTS / 200140885.2Attorney Docket No. DCP-147WO than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state salt form of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state salt form of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state salt form of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state salt form of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state salt form of the compound has no more than about 5 mol% of other solid- state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state salt form of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state salt form of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state salt form of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state salt form of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[0003311 Also provided herein are pharmaceutical compositions comprising the crystalline solid-state salt form of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000332] In some embodiments, the crystalline solid-state salt form is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state salt form is present in the composition in an amount of at least about 85% by weight. In some embodiments, the crystalline solid-state salt form is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state salt form is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state salt form is present in the composition in an amount of at42IPTS / 200140885.2Attorney Docket No. DCP-147WO least about 96% by weight. In some embodiments, the crystalline solid-state salt form is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state salt form is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state salt form is present in the composition in an amount of at least about 99% by weight.[000333] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state salt form of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state salt form of the compound represented by Formula (I), which is in the form of a tablet. In some embodiments, the composition is for oral administration.[000334] Also provided herein, in some embodiments, are pharmaceutical compositions consisting essentially of the crystalline solid-state salt form described herein, or combinations thereof, and a pharmaceutically acceptable carrier. In some embodiments, the composition is for oral administration.Hydrobromide Salt Forms of the Compound of Formula (I)[000335] Provided herein, in some embodiments, are amorphous solid-state hydrobromide salt forms of the compound represented by Formula (I):or a solvate thereof. In some embodiments, the amorphous solid-state hydrobromide salt form has an XRPD pattern exhibiting a broad peak (halo pattern), in terms of 2-theta, that extends from about 10° to about 30°. In some embodiments, the amorphous solid-state hydrobromide salt form has an XRPD pattern substantially as shown in FIG. IB.43IPTS / 200140885.2Attorney Docket No. DCP-147WO[000336] In some embodiments, provided herein is an amorphous solid-state hydrobromide salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (c.g., about 40 °C / about 75% relative humidity (RH)) to obtain the amorphous solid-state form.[000337] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is a ketone. In some embodiments, the solvent in step (i) is MEK.[000338] In some embodiments, the acid in step (ii) is hydrobromic acid.[000339] Provided herein, in some embodiments, is a process for preparing an amorphous solid-state hydrobromide salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., about 40 °C / about 75% relative humidity (RH)) to obtain the amorphous solid-state form.44IPTS / 200140885.2Attorney Docket No. DCP-147WO[000340] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is a ketone. In some embodiments, the solvent in step (i) is MEK.[000341] In some embodiments, the acid in step (ii) is hydrobromic acid.[000342] In some embodiments, the amorphous solid-state hydrobromide salt form of the compound is substantially pure. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound is essentially free of solvents.[000343] In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has a chemical purity of greater than 99% by weight.[000344] In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state hydrobromide salt form of the compound has no more than about 9 mol% of other solid- state forms of the compound represented by Formula (I), or a solvate thereof. In some45IPTS / 200140885.2Attorney Docket No. DCP-147WO embodiments, the amorphous solid-state hydrobromide salt form of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state hydrobromide salt form of the compound has no more than about 6 mol% of other solid- state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state hydrobromide salt form of the compound has no more than about 3 mol% of other solid- state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state hydrobromide salt form of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000345] Also provided herein are pharmaceutical compositions comprising the amorphous solid-state hydrobromide salt form of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000346] In some embodiments, the amorphous solid-state hydrobromide salt form is present in the composition in an amount of at least about 80% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form is present in the composition in an amount of at least about 85% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form is present in the composition in an amount of at least about 90% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form is present in the composition in an amount of at least about 95% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form is present in the composition in an amount of at least about 96% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form is present in46IPTS / 200140885.2Attorney Docket No. DCP-147WO the composition in an amount of at least about 97% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form is present in the composition in an amount of at least about 98% by weight. In some embodiments, the amorphous solid-state hydrobromide salt form is present in the composition in an amount of at least about 99% by weight.[000347] In some embodiments, provided herein is a pharmaceutical composition comprising the amorphous solid-state hydrobromide salt form of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the amorphous solid-state hydrobromide salt form of the compound represented by Formula (I), which is in the form of a tablet. In some embodiments, the composition is for oral administration.[000348] Also provided herein, in some embodiments, are pharmaceutical compositions consisting essentially of the amorphous solid-state hydrobromide salt form described herein, or combinations thereof, and a pharmaceutically acceptable carrier. In some embodiments, the composition is for oral administration.[000349] Provided herein, in some embodiments, are crystalline solid-state hydrobromide salt forms of the compound represented by Formula (I):or a solvate thereof.Form I[000350] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 7.80°, about 15.64°, and about 22.41°.[000351] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 7.8°, about 15.6°, and about 22.4°.47IPTS / 200140885.2Attorney Docket No. DCP-147WO[000352] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 7.80°, about 8.83°, about 15.64°, about 22.41°, and about 23.02°.[000353] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 7.8°, about 8.8°, about 15.6°, about 22.4°, and about 23.0°.[000354] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 7.80°, about 8.83°, about 9.95°, about 15.64°, about 22.41°, about 21.96°, and about 23.02°.[000355] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 7.8°, about 8.8°, about 10.0°, about 15.6°, about 22.4°, about 22.0°, and about 23.0°.[000356] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form I, having an XRPD pattern substantially as shown in FIG. 1J.[000357] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form I, having a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at about 209 °C.[000358] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form I, having a DSC thermogram substantially as shown in FIG. 1 G.[000359] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form I, having a therm ogravimetric (“TG”) analysis / differential scanning calorimetry (DSC) analysis thermogram substantially as shown in FIG. IF.[000360] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form I, having a 'H nuclear magnetic resonance (NMR) spectrum substantially as shown in FIG. 1H.48IPTS / 200140885.2Attorney Docket No. DCP-147WO[000361] In some embodiments, provided herein is a crystalline solid-state hydrobromide salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) drying the solid precipitate in (iv) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form.[000362] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is a ketone, an ester, or an ether. In some embodiments, the solvent in step (i) is 2-MeTHF. In some embodiments, the solvent in step (i) is acetone. In some embodiments, the solvent in step (i) is ethyl acetate. In some embodiments, the solvent in step (i) is MEK.[000363] In some embodiments, the acid in step (ii) is hydrobromic acid. In some embodiments, the acid in step (ii) is hydrogen bromide (e.g., gaseous hydrogen bromide). In some embodiments, the acid in step (ii) is hydrogen bromide (e.g, gaseous hydrogen bromide) in a suitable solvent (e.g., alcohol, dioxane).[000364] In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound is substantially pure. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound is essentially free of solvents.[000365] In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I49IPTS / 200140885.2Attorney Docket No. DCP-147WO of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has a chemical purity of greater than 99% by weight.[000366] In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments,50IPTS / 200140885.2Attorney Docket No. DCP-147WO the crystalline solid-state hydrobromide salt Form I of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form I of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000367] Also provided herein are pharmaceutical compositions comprising the crystalline solid-state hydrobromide salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000368] In some embodiments, the crystalline solid-state hydrobromide salt Form I is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I is present in the composition in an amount of at least about 85% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I is present in the composition in an amount of at least about 96% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form I is present in the composition in an amount of at least about 99% by weight.[000369] Also provided herein are pharmaceutical compositions consisting essentially of the crystalline solid-state hydrobromide salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000370] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state hydrobromide salt Form I of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state hydrobromide salt Form I of the compound represented by Formula (I), which is in the form of a tablet.51IPTS / 200140885.2Attorney Docket No. DCP-147WO[000371] Provided herein, in some embodiments, is a process for preparing a crystalline solid-state hydrobromide salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g, between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) drying the solid precipitate in (iv) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form.[000372] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is a ketone, an ester, or an ether. In some embodiments, the solvent in step (i) is 2-MeTHF. In some embodiments, the solvent in step (i) is acetone. In some embodiments, the solvent in step (i) is ethyl acetate. In some embodiments, the solvent in step (i) is MEK.[000373] In some embodiments, the acid in step (ii) is hydrobromic acid. In some embodiments, the acid in step (ii) is hydrogen bromide (e.g, gaseous hydrogen bromide). In some embodiments, the acid in step (ii) is hydrogen bromide (e.g, gaseous hydrogen bromide) in a suitable solvent (e.g, alcohol, dioxane).Form II[000374] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 7.44°, about 18.15°, and about 19.28°.[000375] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 7.4°, about 18.2°, and about 19.3°.[000376] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 7.44°, about 18.15°, about 18.79°, about 19.28°, and about 23.87°.52IPTS / 200140885.2Attorney Docket No. DCP-147WO[000377] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 7.4°, about 18.2°, about 18.8°, about 19.3°, and about 23.9°.[000378] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form II, having an (XRPD pattern comprising peaks, in terms of 2-theta, at about 7.44°, about 14.91°, about 18.15°, about 18.79°, about 19.28°, about 23.87°, and about 26.46°.[000379] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 7.4°, about 14.9°, about 18.2°, about 18.8°, about 19.3°, about 23.9°, and about 26.5°.[000380] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form II, having an XRPD pattern substantially as shown in FIG. 2A.[000381] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form II, having a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at about 210 °C.[000382] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form II, having a DSC thermogram substantially as shown in FIG. 2C.[000383] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form II, having a TG / DSC thermogram substantially as shown in FIG. 2B.[000384] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form II, having anuclear magnetic resonance (NMR) spectrum substantially as shown in FIG. 2G.[000385] In some embodiments, the crystalline solid-state hydrobromide salt form is crystalline solid-state hydrobromide salt Form II, wherein the crystalline solid-state salt form is a hydrate.[000386] In some embodiments, the hydrate is a monohydrate.53IPTS / 200140885.2Attorney Docket No. DCP-147WO[000387] In some embodiments, provided herein is a crystalline solid-state hydrobromide salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (c.g, about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid-state form.[000388] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ester. In some embodiments, the solvent in step (i) is ethyl acetate.[000389] In some embodiments, the acid in step (ii) is hydrobromic acid. In some embodiments, the acid in step (ii) is hydrogen bromide (c.g., gaseous hydrogen bromide). In some embodiments, the acid in step (ii) is hydrogen bromide (c.g, gaseous hydrogen bromide) in a suitable solvent (e.g, alcohol, dioxane).[000390] In some embodiments, provided herein is a crystalline solid-state hydrobromic salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g, between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);54IPTS / 200140885.2Attorney Docket No. DCP-147WO(vi) temperature cycling the mixture from step (v) (e.g, between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) filtering the mixture from step (vi) (e.g, via centrifugation) to obtain a solid precipitate; and(viii) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g, about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid- state form.[000391] In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step (i) is an alcohol. In some embodiments, the solvent in step (i) is ethanol.[000392] In some embodiments, the acid in step (ii) is hydrobromic acid. In some embodiments, the acid in step (ii) is hydrogen bromide (e.g., gaseous hydrogen bromide). In some embodiments, the acid in step (ii) is hydrogen bromide (e.g., gaseous hydrogen bromide) in a suitable solvent (e.g, alcohol, dioxane).[000393] In some embodiments, the solvent in step (v) is tert-butyl methyl ether.[000394] In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound is substantially pure. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound is essentially free of solvents.[000395] In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has a chemical purity of greater than 98% by weight. In some55IPTS / 200140885.2Attorney Docket No. DCP-147WO embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has a chemical purity of greater than 99% by weight.[0003961 In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrobromide salt Form II of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.56IPTS / 200140885.2Attorney Docket No. DCP-147WO[000397] Also provided herein are pharmaceutical compositions comprising the crystalline solid-state hydrobromide salt Form II of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000398] In some embodiments, the crystalline solid-state hydrobromide salt Form II is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II is present in the composition in an amount of at least about 85% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II is present in the composition in an amount of at least about 96% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state hydrobromide salt Form II is present in the composition in an amount of at least about 99% by weight.[000399] Also provided herein are pharmaceutical compositions consisting essentially of the crystalline solid-state hydrobromide salt Form II of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000400] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state hydrobromide salt Form II of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state hydrobromide salt Form II of the compound represented by Formula (I), which is in the form of a tablet.[000401] Provided herein, in some embodiments, is a process for preparing a crystalline solid-state hydrobromide salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);57IPTS / 200140885.2Attorney Docket No. DCP-147WO(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) (e.g., via centrifugation) to obtain a solid precipitate; and(v) drying the solid precipitate in (iv) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form.[000402] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ester. In some embodiments, the solvent in step (i) is ethyl acetate.[000403] In some embodiments, the acid in step (ii) is hydrobromic acid. In some embodiments, the acid in step (ii) is hydrogen bromide (e.g., gaseous hydrogen bromide). In some embodiments, the acid in step (ii) is hydrogen bromide (e.g., gaseous hydrogen bromide) in a suitable solvent (e.g., alcohol, dioxane).[000404] Provided herein, in some embodiments, is a process for preparing a crystalline solid-state hydrobromide salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) fdtering the mixture from step (vi) (e.g., via centrifugation) to obtain a solid precipitate; and(viii) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid- state form.58IPTS / 200140885.2Attorney Docket No. DCP-147WO[000405] In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step (i) is an alcohol. In some embodiments, the solvent in step (i) is ethanol.[000406] some embodiments, the acid in step (ii) is hydrobromic acid. In some embodiments, the acid in step (ii) is hydrogen bromide (e.g., gaseous hydrogen bromide). In some embodiments, the acid in step (ii) is hydrogen bromide (e.g., gaseous hydrogen bromide) in a suitable solvent (e.g., alcohol, dioxane).[000407] In some embodiments, the solvent in step (v) is tert-butyl methyl ether.Hydrochloride Salt Forms of the Compound of Formula (I)[000408] Provided herein, in some embodiments, are amorphous solid-state hydrochloride salt forms of the compound represented by Formula (I):or a solvate thereof. In some embodiments, the amorphous solid-state hydrochloride salt form has an XRPD pattern exhibiting a broad peak (halo pattern), in terms of 2-theta, that extends from about 10° to about 30°. In some embodiments, the amorphous solid-state hydrochloride salt form has an XRPD pattern substantially as shown in FIG. 3A. In some embodiments, the amorphous solid-state hydrochloride salt form has an XRPD pattern substantially as shown in FIG. 3B.[000409] In some embodiments, provided herein is an amorphous solid-state hydrochloride salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);59IPTS / 200140885.2Attorney Docket No. DCP-147WO(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) fdtering the mixture from step (vi) (e.g., via centrifugation) to obtain a solid precipitate; and(viii) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., about 40 °C / about 75% relative humidity (RH)) to obtain the amorphous solid- state form.[000410] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is a ketone. In some embodiments, the solvent in step (i) is acetone.[000411] In some embodiments, the acid in step (ii) is hydrochloric acid. In some embodiments, the acid in step (ii) is hydrogen chloride (e.g., gaseous hydrogen chloride). In some embodiments, the acid in step (ii) is hydrogen chloride (e.g., gaseous hydrogen chloride) in a suitable solvent (e.g., alcohol, dioxane).[000412] In some embodiments, the solvent in step (v) is tert-butyl methyl ether.[000413] Provided herein, in some embodiments, is a process for preparing an amorphous solid-state hydrochloride salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);60IPTS / 200140885.2Attorney Docket No. DCP-147WO(vii) filtering the mixture from step (vi) (e.g, via centrifugation) to obtain a solid precipitate; and(viii) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., about 40 °C / about 75% relative humidity (RH)) to obtain the amorphous solid- state form .[000414] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is a ketone. In some embodiments, the solvent in step (i) is acetone.[000415] In some embodiments, the acid in step (ii) is hydrochloric acid. In some embodiments, the acid in step (ii) is hydrogen chloride (e.g., gaseous hydrogen chloride). In some embodiments, the acid in step (ii) is hydrogen chloride (e.g., gaseous hydrogen chloride) in a suitable solvent (e.g., alcohol, dioxane).[000416] In some embodiments, the solvent in step (v) is tert-butyl methyl ether.[000417] In some embodiments, the amorphous solid-state hydrochloride salt form of the compound is substantially pure. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound is essentially free of solvents.[000418] In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has a chemical purity of greater than 99% by weight.61IPTS / 200140885.2Attorney Docket No. DCP-147WO[000419] In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state hydrochloride salt form of the compound has no more than about 9 mol% of other solid- state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state hydrochloride salt form of the compound has no more than about 6 mol% of other solid- state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state hydrochloride salt form of the compound has no more than about 3 mol% of other solid- state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state hydrochloride salt form of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.62IPTS / 200140885.2Attorney Docket No. DCP-147WO[000420] Also provided herein are pharmaceutical compositions comprising the amorphous solid-state hydrochloride salt form of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000421] In some embodiments, the amorphous solid-state hydrochloride salt form is present in the composition in an amount of at least about 80% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form is present in the composition in an amount of at least about 85% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form is present in the composition in an amount of at least about 90% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form is present in the composition in an amount of at least about 95% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form is present in the composition in an amount of at least about 96% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form is present in the composition in an amount of at least about 97% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form is present in the composition in an amount of at least about 98% by weight. In some embodiments, the amorphous solid-state hydrochloride salt form is present in the composition in an amount of at least about 99% by weight.[000422] In some embodiments, provided herein is a pharmaceutical composition comprising the amorphous solid-state hydrochloride salt form of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the amorphous solid-state hydrochloride salt form of the compound represented by Formula (I), which is in the form of a tablet. In some embodiments, the composition is for oral administration.[000423] Also provided herein, in some embodiments, are pharmaceutical compositions consisting essentially of the amorphous solid-state hydrochloride salt form described herein, or combinations thereof, and a pharmaceutically acceptable carrier. In some embodiments, the composition is for oral administration.[000424] Provided herein, in some embodiments, are crystalline solid-state hydrochloride salt forms of the compound represented by Formula (I):63IPTS / 200140885.2Attorney Docket No. DCP-147WOor a solvate thereof.Form I[000425] In some embodiments, the crystalline solid-state hydrochloride salt form is crystalline solid-state hydrochloride salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 15.93°, about 17.48°, and about 22.10°.[000426] In some embodiments, the crystalline solid-state hydrochloride salt form is crystalline solid-state hydrochloride salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 15.9°, about 17.5°, and about 22.1°.[000427] In some embodiments, the crystalline solid-state hydrochloride salt form is crystalline solid-state hydrochloride salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 11.75°, about 13.86°, about 15.93°, about 17.48°, and about 22.10°.[000428] In some embodiments, the crystalline solid-state hydrochloride salt form is crystalline solid-state hydrochloride salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 11.8°, about 13.9°, about 15.9°, about 17.5°, and about 22.1°.[000429] In some embodiments, the crystalline solid-state hydrochloride salt form is crystalline solid-state hydrochloride salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 11.75°, about 13.86°, about 15.93°, about 17.48°, about 22.10°, about 22.48°, and about 26.50°.[000430] In some embodiments, the crystalline solid-state hydrochloride salt form is crystalline solid-state hydrochloride salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 11.8°, about 13.9°, about 15.9°, about 17.5°, about 22.1°, about 22.5°, and about 26.5°.64IPTS / 200140885.2Attorney Docket No. DCP-147WO[000431] In some embodiments, the crystalline solid-state hydrochloride salt form is crystalline solid-state hydrochloride salt Form I, having an XRPD pattern substantially as shown in FIG. 3E.[000432] In some embodiments, the crystalline solid-state hydrochloride salt form is crystalline solid-state hydrochloride salt Form I, having a TG / DSC thermogram substantially as shown in FIG. 3C.[000433] In some embodiments, the crystalline solid-state hydrochloride salt form is crystalline solid-state hydrochloride salt Form I, having a 'H nuclear magnetic resonance (NMR) spectrum substantially as shown in FIG. 3D.[000434] In some embodiments, provided herein is a crystalline solid-state hydrochloride salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) (e.g., via centrifugation) to obtain a solid precipitate; and(v) drying the solid precipitate in (iv) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form.[000435] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ester, or an ether. In some embodiments, the solvent in step (i) is 2-MeTHF. In some embodiments, the solvent in step (i) is ethyl acetate.[000436] In some embodiments, the acid in step (ii) is hydrochloric acid. In some embodiments, the acid in step (ii) is hydrogen chloride (e.g., gaseous hydrogen chloride ). In some embodiments, the acid in step (ii) is hydrogen chloride (e.g., gaseous hydrogen chloride) in a suitable solvent (e.g., alcohol, dioxane).[000437] In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound is substantially pure. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound is essentially free of solvents.65IPTS / 200140885.2Attorney Docket No. DCP-147WO[000438] In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has a chemical purity of greater than 99% by weight.[000439] In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments,66IPTS / 200140885.2Attorney Docket No. DCP-147WO the crystalline solid-state hydrochloride salt Form T of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state hydrochloride salt Form I of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000440] Also provided herein are pharmaceutical compositions comprising the crystalline solid-state hydrochloride salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000441] In some embodiments, the crystalline solid-state hydrochloride salt Form I is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I is present in the composition in an amount of at least about 85% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I is present in the composition in an amount of at least about 96% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state hydrochloride salt Form I is present in the composition in an amount of at least about 99% by weight.[000442] Also provided herein are pharmaceutical compositions consisting essentially of the crystalline solid-state hydrochloride salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.67IPTS / 200140885.2Attorney Docket No. DCP-147WO[000443] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state hydrochloride salt Form I of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state hydrochloride salt Form I of the compound represented by Formula (I), which is in the form of a tablet.[000444] Provided herein, in some embodiments, is a process for preparing a crystalline solid-state hydrochloride salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g, between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) drying the solid precipitate in (iv) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form.[000445] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ester, or an ether. In some embodiments, the solvent in step (i) is 2-MeTHF. In some embodiments, the solvent in step (i) is ethyl acetate.[000446] In some embodiments, the acid in step (ii) is hydrochloric acid. In some embodiments, the acid in step (ii) is hydrogen chloride (e.g, gaseous hydrogen chloride). In some embodiments, the acid in step (ii) is hydrogen chloride (e.g., gaseous hydrogen chloride) in a suitable solvent (e.g, alcohol, dioxane).Sulfate Salt Forms of the Compound of Formula (I)[000447] Provided herein, in some embodiments, are amorphous solid-state sulfate salt forms of the compound represented by Formula (I):68IPTS / 200140885.2Attorney Docket No. DCP-147WOor a solvate thereof. In some embodiments, the amorphous solid-state sulfate salt form has an XRPD pattern exhibiting a broad peak (halo pattern), in terms of 2-theta, that extends from about 10° to about 30°. In some embodiments, the amorphous solid-state sulfate salt form has an XRPD pattern substantially as shown in FIG. 5A. In some embodiments, the amorphous solid- state sulfate salt form has an XRPD pattern substantially as shown in FIG. 5B.[000448] In some embodiments, provided herein is an amorphous solid-state sulfate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) (e.g., via centrifugation) to obtain a solid precipitate; and(v) drying the solid precipitate in (iv) (e.g., under reduced pressure (e.g, vacuum)) to obtain the amorphous solid-state form.[000449] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is a ketone. In some embodiments, the solvent in step (i) is acetone. In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step (i) is ethanol.[000450] In some embodiments, the acid in step (ii) is sulfuric acid.[000451] Provided herein, in some embodiments, is a process for preparing an amorphous solid-state sulfate salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;69IPTS / 200140885.2Attorney Docket No. DCP-147WO(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) drying the solid precipitate in (iv) (e.g., under reduced pressure (e.g., vacuum)) to obtain the amorphous solid-state form.[000452] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is a ketone. In some embodiments, the solvent in step (i) is acetone. In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step (i) is ethanol.[000453] In some embodiments, the acid in step (ii) is sulfuric acid.[000454] In some embodiments, the amorphous solid-state sulfate salt form of the compound is substantially pure. In some embodiments, the amorphous solid-state sulfate salt form of the compound is essentially free of solvents.[000455] In some embodiments, the amorphous solid-state sulfate salt form of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the amorphous solid-state sulfate salt form of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the amorphous solid-state sulfate salt form of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the amorphous solid-state sulfate salt form of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the amorphous solid-state sulfate salt form of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the amorphous solid-state sulfate salt form of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the amorphous solid-state sulfate salt form of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the amorphous solid-state sulfate salt form of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the amorphous solid-state sulfate salt form of the compound has a chemical purity of greater than 99% by weight.70IPTS / 200140885.2Attorney Docket No. DCP-147WO[000456] In some embodiments, the amorphous solid-state sulfate salt form of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state sulfate salt form of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state sulfate salt form of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state sulfate salt form of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state sulfate salt form of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state sulfate salt form of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state sulfate salt form of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state sulfate salt form of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state sulfate salt form of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state sulfate salt form of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state sulfate salt form of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000457] Also provided herein are pharmaceutical compositions comprising the amorphous solid-state sulfate salt form of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.71IPTS / 200140885.2Attorney Docket No. DCP-147WO[000458] In some embodiments, the amorphous solid-state sulfate salt form is present in the composition in an amount of at least about 80% by weight. In some embodiments, the amorphous solid-state sulfate salt form is present in the composition in an amount of at least about 85% by weight. In some embodiments, the amorphous solid-state sulfate salt form is present in the composition in an amount of at least about 90% by weight. In some embodiments, the amorphous solid-state sulfate salt form is present in the composition in an amount of at least about 95% by weight. In some embodiments, the amorphous solid-state sulfate salt form is present in the composition in an amount of at least about 96% by weight. In some embodiments, the amorphous solid-state sulfate salt form is present in the composition in an amount of at least about 97% by weight. In some embodiments, the amorphous solid-state sulfate salt form is present in the composition in an amount of at least about 98% by weight. In some embodiments, the amorphous solid-state sulfate salt form is present in the composition in an amount of at least about 99% by weight.[000459] In some embodiments, provided herein is a pharmaceutical composition comprising the amorphous solid-state sulfate salt form of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the amorphous solid-state sulfate salt form of the compound represented by Formula (I), which is in the form of a tablet. In some embodiments, the composition is for oral administration.[000460] Also provided herein, in some embodiments, are pharmaceutical compositions consisting essentially of the amorphous solid-state sulfate salt form described herein, or combinations thereof, and a pharmaceutically acceptable carrier. In some embodiments, the composition is for oral administration.[000461] Provided herein, in some embodiments, are crystalline solid-state sulfate salt forms of the compound represented by Formula (I):72IPTS / 200140885.2Attorney Docket No. DCP-147WOor a solvate thereof.Form I[000462] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.60°, about 13.00°, and about 26.34°.[000463] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.6°, about 13.0°, and about 26.3°.[000464] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.60°, about 13.00°, about 16.39°, about 24.94°, and about 26.34°.[000465] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.6°, about 13.0°, about 16.4°, about 24.9°, and about 26.3°.[000466] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.60°, about 13.00°, about 16.39°, about 17.47°, about 24.94°, about 26.34°, and about 29.77°.[000467] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.6°, about 13.0°, about 16.4°, about 17.5°, about 24.9°, about 26.3°, and about 29.8°.[000468] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form I, having an XRPD pattern substantially as shown in FIG. 5G.IPTS / 200140885.2Attorney Docket No. DCP-147WO[000469] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form I, having a TG / DSC thermogram substantially as shown in FIG. 5C. [000470] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form I, having aJH nuclear magnetic resonance (NMR) spectrum substantially as shown in FIG. 5D.[000471] In some embodiments, provided herein is a crystalline solid-state sulfate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (c.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid- state form.[000472] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is a ketone. In some embodiments, the solvent in step (i) is acetone.[000473] In some embodiments, the acid in step (ii) is sulfuric acid.[000474] In some embodiments, the crystalline solid-state sulfate salt Form I of the compound is substantially pure.[000475] In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the74IPTS / 200140885.2Attorney Docket No. DCP-147WO crystalline solid-state sulfate salt Form T of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has a chemical purity of greater than 99% by weight.[000476] In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form I of the compound has no more than about 2 mol% of other solid-state forms of the compound75IPTS / 200140885.2Attorney Docket No. DCP-147WO represented by Formula (I), or a solvate thereof. Tn some embodiments, the crystalline solid-state sulfate salt Form I of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000477] Also provided herein are pharmaceutical compositions comprising the crystalline solid-state sulfate salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000478] In some embodiments, the crystalline solid-state sulfate salt Form I is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I is present in the composition in an amount of at least about 85% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I is present in the composition in an amount of at least about 96% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state sulfate salt Form I is present in the composition in an amount of at least about 99% by weight.[000479] Also provided herein are pharmaceutical compositions consisting essentially of the crystalline solid-state sulfate salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000480] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state sulfate salt Form I of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state sulfate salt Form I of the compound represented by Formula (I), which is in the form of a tablet.[000481] Provided herein, in some embodiments, is a process for preparing a crystalline solid-state sulfate salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;76IPTS / 200140885.2Attorney Docket No. DCP-147WO(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid- state form.[000482] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is a ketone. In some embodiments, the solvent in step (i) is acetone.[000483] In some embodiments, the acid in step (ii) is sulfuric acid.Form II[000484] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 18.03°, about 20.79°, and about 22.32°.[000485] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 18.0°, about 20.8°, and about 22.3°.[000486] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 17.57°, about 18.03°, about 20.79°, about 22.32°, and about 23.78°.[000487] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 17.6°, about 18.0°, about 20.8°, about 22.3°, and about 23.8°.[000488] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.58°, about 17.57°, about 18.03°, about 20.79°, about 22.32°, about 23.78°, and about 26.28°.77IPTS / 200140885.2Attorney Docket No. DCP-147WO[000489] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.6°, about 17.6°, about 18.0°, about 20.8°, about 22.3°, about 23.8°, and about 26.3°.[000490] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form II, having an XRPD pattern substantially as shown in FIG. 5H.[000491] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form II, having a TG / DSC thermogram substantially as shown in FIG. 5E.[000492] In some embodiments, the crystalline solid-state sulfate salt form is crystalline solid-state sulfate salt Form II, having arH nuclear magnetic resonance (NMR) spectrum substantially as shown in FIG. 5F.[000493] In some embodiments, provided herein is a crystalline solid-state sulfate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) (e.g., via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid- state form.[000494] In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step (i) is an alcohol. In some embodiments, the solvent in step (i) is ethanol.[000495] In some embodiments, the acid in step (ii) is sulfuric acid.[000496] In some embodiments, the crystalline solid-state sulfate salt Form II of the compound is substantially pure. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound is essentially free of solvents.[000497] In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the78IPTS / 200140885.2Attorney Docket No. DCP-147WO crystalline solid-state sulfate salt Form TI of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has a chemical purity of greater than 99% by weight.[000498] In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the79IPTS / 200140885.2Attorney Docket No. DCP-147WO crystalline solid-state sulfate salt Form TI of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state sulfate salt Form II of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000499] Also provided herein are pharmaceutical compositions comprising the crystalline solid-state sulfate salt Form II of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000500] In some embodiments, the crystalline solid-state sulfate salt Form II is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II is present in the composition in an amount of at least about 85% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II is present in the composition in an amount of at least about 96% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state sulfate salt Form II is present in the composition in an amount of at least about 99% by weight.[000501] Also provided herein are pharmaceutical compositions consisting essentially of the crystalline solid-state sulfate salt Form II of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000502] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state sulfate salt Form II of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a80IPTS / 200140885.2Attorney Docket No. DCP-147WO pharmaceutical composition comprising the crystalline solid-state sulfate salt Form II of the compound represented by Formula (I), which is in the form of a tablet.[0005031 Provided herein, in some embodiments, is a process for preparing a crystalline solid-state sulfate salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) (e.g., via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid- state form.[000504] In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step (i) is an alcohol. In some embodiments, the solvent in step (i) is ethanol.[000505] In some embodiments, the acid in step (ii) is sulfuric acid.Edisylate Salt Forms of the Compound of Formula (J)[000506] Provided herein, in some embodiments, are amorphous solid-state edisylate salt forms of the compound represented by Formula (I):or a solvate thereof. In some embodiments, the amorphous solid-state edisylate salt form has an XRPD pattern exhibiting a broad peak (halo pattern), in terms of 2-theta, that extends from about 10° to about 30°. In some embodiments, the amorphous solid-state edisylate salt form has an81IPTS / 200140885.2Attorney Docket No. DCP-147WOXRPD pattern substantially as shown in FIG. 6A. In some embodiments, the amorphous solid- state edisylate salt form has an XRPD pattern substantially as shown in FIG. 6B.[0005071 Insome embodiments, provided herein is an amorphous solid-state edisylate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g, between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) fdtering the mixture from step (vi) (e.g, via centrifugation) to obtain a solid precipitate; and(viii) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g, at about 40 °C / about 75% relative humidity (RH)) to obtain the amorphous solid-state form.[000508] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ether. In some embodiments, the solvent in step (i) is 2- MeTHF.[000509] In some embodiments, the acid in step (ii) is 1,2-ethanedisulfonic acid.[000510] Provided herein, in some embodiments, is a process for preparing an amorphous solid-state edisylate salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);82IPTS / 200140885.2Attorney Docket No. DCP-147WO(vi) temperature cycling the mixture from step (v) (e.g, between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) filtering the mixture from step (vi) (e.g, via centrifugation) to obtain a solid precipitate; and(viii) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g, at about 40 °C / about 75% relative humidity (RH)) to obtain the amorphous solid-state form.[000511] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ether. In some embodiments, the solvent in step (i) is 2- MeTHF.[000512] In some embodiments, the acid in step (ii) is 1,2-ethanedisulfonic acid.[000513] In some embodiments, the amorphous solid-state edisylate salt form of the compound is substantially pure. In some embodiments, the amorphous solid-state edisylate salt form of the compound is essentially free of solvents.[000514] In some embodiments, the amorphous solid-state edisylate salt form of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the amorphous solid-state edisylate salt form of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the amorphous solid-state edisylate salt form of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the amorphous solid-state edisylate salt form of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the amorphous solid-state edisylate salt form of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the amorphous solid-state edisylate salt form of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the amorphous solid-state edisylate salt form of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the amorphous solid-state edisylate salt form of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the amorphous solid-state edisylate salt form of the compound has a chemical purity of greater than 99% by weight.[000515] In some embodiments, the amorphous solid-state edisylate salt form of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no83IPTS / 200140885.2Attorney Docket No. DCP-147WO more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state edisylate salt form of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state edisylate salt form of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state edisylate salt form of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state edisylate salt form of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state edisylate salt form of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state edisylate salt form of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state edisylate salt form of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state edisylate salt form of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state edisylate salt form of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state edisylate salt form of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000516] Also provided herein are pharmaceutical compositions comprising the amorphous solid-state edisylate salt form of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000517] In some embodiments, the amorphous solid-state edisylate salt form is present in the composition in an amount of at least about 80% by weight. In some embodiments, the amorphous solid-state edisylate salt form is present in the composition in an amount of at least84IPTS / 200140885.2Attorney Docket No. DCP-147WO about 85% by weight. In some embodiments, the amorphous solid-state edisylate salt form is present in the composition in an amount of at least about 90% by weight. In some embodiments, the amorphous solid-state edisylate salt form is present in the composition in an amount of at least about 95% by weight. In some embodiments, the amorphous solid-state edisylate salt form is present in the composition in an amount of at least about 96% by weight. In some embodiments, the amorphous solid-state edisylate salt form is present in the composition in an amount of at least about 97% by weight. In some embodiments, the amorphous solid-state edisylate salt form is present in the composition in an amount of at least about 98% by weight. In some embodiments, the amorphous solid-state edisylate salt form is present in the composition in an amount of at least about 99% by weight.[000518] In some embodiments, provided herein is a pharmaceutical composition comprising the amorphous solid-state edisylate salt form of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the amorphous solid-state edisylate salt form of the compound represented by Formula (I), which is in the form of a tablet. In some embodiments, the composition is for oral administration.[000519] Also provided herein, in some embodiments, are pharmaceutical compositions consisting essentially of the amorphous solid-state edisylate salt form described herein, or combinations thereof, and a pharmaceutically acceptable carrier. In some embodiments, the composition is for oral administration.[000520] Provided herein, in some embodiments, are crystalline solid-state edisylate salt forms of the compound represented by Formula (I):or a solvate thereof. Form I85IPTS / 200140885.2Attorney Docket No. DCP-147WO[000521] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 15.10°, about 18.30°, and about 21.66°.[000522] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 15.1°, about 18.3°, and about 21.7°.[000523] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 9.65°, about 15.10°, about 18.30°, about 21.66°, and about 24.81°.[000524] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 9.7°, about 15.1°, about 18.3°, about 21.7°, and about 24.8°.[000525] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 9.65°, about 15.10°, about 16.54°, about 18.30°, about 20.89°, about 21.66°, and about 24.81°.[000526] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 9.7°, about 15.1°, about 16.5°, about 18.3°, about 20.9°, about 21.7°, and about 24.8°.[000527] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form I, having an XRPD pattern substantially as shown in FIG. 6F.[000528] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form I, having a DSC thermogram substantially as shown in FIG. 6D.[000529] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form I, having a TG / DSC thermogram substantially as shown in FIG. 6C.[000530] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form I, having a 'H nuclear magnetic resonance (NMR) spectrum substantially as shown in FIG. 6E.[000531] In some embodiments, provided herein is a crystalline solid-state edisylate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:86IPTS / 200140885.2Attorney Docket No. DCP-147WO(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) (e.g., via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid- state form.[000532] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ether, or a ketone. In some embodiments, the solvent in step (i) is 2-MeTHF. In some embodiments, the solvent in step (i) is acetone.[000533] In some embodiments, the acid in step (ii) is 1,2-ethanedisulfonic acid.[000534] In some embodiments, the crystalline solid-state edisylate salt Form I of the compound is substantially pure. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound is essentially free of solvents.[000535] In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has a chemical purity of greater than 99% by weight.87IPTS / 200140885.2Attorney Docket No. DCP-147WO[000536] In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form I of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000537] Also provided herein are pharmaceutical compositions comprising the crystalline solid-state edisylate salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.88IPTS / 200140885.2Attorney Docket No. DCP-147WO[000538] In some embodiments, the crystalline solid-state edisylate salt Form I is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I is present in the composition in an amount of at least about 85% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I is present in the composition in an amount of at least about 96% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state edisylate salt Form I is present in the composition in an amount of at least about 99% by weight.[000539] Also provided herein are pharmaceutical compositions consisting essentially of the crystalline solid-state edisylate salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000540] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state edisylate salt Form I of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state edisylate salt Form I of the compound represented by Formula (I), which is in the form of a tablet.[000541] Provided herein, in some embodiments, is a process for preparing a crystalline solid-state edisylate salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) (e.g., via centrifugation) to obtain a solid precipitate; and89IPTS / 200140885.2Attorney Docket No. DCP-147WO(v) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g.. at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid- state form.[000542] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ether, or a ketone. In some embodiments, the solvent in step (i) is 2-MeTHF. In some embodiments, the solvent in step (i) is acetone.[000543] In some embodiments, the acid in step (ii) is 1,2-ethanedisulfonic acid.Form II[000544] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 9.70°, about 15.48°, and about 19.43°.[000545] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 9.7°, about 15.5°, and about 19.4°.[000546] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 5.51°, about 9.70°, about 13.73°, about 15.48°, and about 19.43°.[000547] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 5.5°, about 9.7°, about 13.7°, about 15.5°, and about 19.4°.[000548] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 5.51°, about 9.70°, about 13.73°, about 15.48°, about 19.43°, about 23.78°, and about 26.50°.[000549] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 5.5°, about 9.7°, about 13.7°, about 15.5°, about 19.4°, about 23.8°, and about 26.5°.[000550] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form II, having an XRPD pattern substantially as shown in FIG. 6G.[000551] In some embodiments, provided herein is a crystalline solid-state edisylate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:90IPTS / 200140885.2Attorney Docket No. DCP-147WO(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) (e.g., via centrifugation) to obtain a solid precipitate; and(v) drying the solid precipitate in (iv) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form.[000552] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ester. In some embodiments, the solvent in step (i) is ethyl acetate.[000553] In some embodiments, the acid in step (ii) is 1,2-ethanedisulfonic acid.[000554] In some embodiments, the crystalline solid-state edisylate salt Form II of the compound is substantially pure. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound is essentially free of solvents.[000555] In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has a chemical purity of greater than 99% by weight.91IPTS / 200140885.2Attorney Docket No. DCP-147WO[000556] In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form II of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000557] Also provided herein are pharmaceutical compositions comprising the crystalline solid-state edisylate salt Form II of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.92IPTS / 200140885.2Attorney Docket No. DCP-147WO[000558] In some embodiments, the crystalline solid-state edisylate salt Form II is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II is present in the composition in an amount of at least about 85% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II is present in the composition in an amount of at least about 96% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state edisylate salt Form II is present in the composition in an amount of at least about 99% by weight.[000559] Also provided herein are pharmaceutical compositions consisting essentially of the crystalline solid-state edisylate salt Form II of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000560] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state edisylate salt Form II of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state edisylate salt Form II of the compound represented by Formula (I), which is in the form of a tablet.[000561] Provided herein, in some embodiments, is a process for preparing a crystalline solid-state edisylate salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) (e.g., via centrifugation) to obtain a solid precipitate; and93IPTS / 200140885.2Attorney Docket No. DCP-147WO(v) drying the solid precipitate in (iv) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form.[0005621 Insome embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ester. In some embodiments, the solvent in step (i) is ethyl acetate.[000563] In some embodiments, the acid in step (ii) is 1,2-ethanedisulfonic acid.Form III[000564] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form III, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 15.24°, about 19.31°, and about 21.47°.[000565] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form III, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 15.2°, about 19.3°, and about 21.5°.[000566] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form III, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 15.24°, about 16.23°, about 19.31°, about 21.47°, and about 22.82°.[000567] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form III, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 15.2°, about 16.2°, about 19.3°, about 21.5°, and about 22.8°.[000568] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form III, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 15.24°, about 16.23°, about 17.40°, about 19.31°, about 21.47°, about 22.82°, and about 28.55°.[000569] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form III, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 15.2°, about 16.2°, about 17.4°, about 19.3°, about 21.5°, about 22.8°, and about 28.6°.[000570] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form III, having an XRPD pattern substantially as shown in FIG. 6H.[000571] In some embodiments, provided herein is a crystalline solid-state edisylate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;94IPTS / 200140885.2Attorney Docket No. DCP-147WO(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) filtering the mixture from step (vi) (e.g., via centrifugation) to obtain a solid precipitate; and(viii) drying the solid precipitate in (vii) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form.[000572] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ester. In some embodiments, the solvent in step (i) is ethyl acetate.[000573] In some embodiments, the acid in step (ii) is 1,2-ethanedisulfonic acid.[000574] In some embodiments, the solvent in step (v) is tert-butyl methyl ether.[000575] In some embodiments, the crystalline solid-state edisylate salt Form III of the compound is substantially pure. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound is essentially free of solvents.[000576] In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the95IPTS / 200140885.2Attorney Docket No. DCP-147WO crystalline solid-state edisylate salt Form III of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has a chemical purity of greater than 99% by weight.[000577] In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form III of the compound has no more than about 196IPTS / 200140885.2Attorney Docket No. DCP-147WO mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[0005781 Also provided herein are pharmaceutical compositions comprising the crystalline solid-state edisylate salt Form III of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000579] In some embodiments, the crystalline solid-state edisylate salt Form III is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III is present in the composition in an amount of at least about 85% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III is present in the composition in an amount of at least about 96% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state edisylate salt Form III is present in the composition in an amount of at least about 99% by weight.[000580] Also provided herein are pharmaceutical compositions consisting essentially of the crystalline solid-state edisylate salt Form III of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000581] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state edisylate salt Form III of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state edisylate salt Form III of the compound represented by Formula (I), which is in the form of a tablet.[000582] Provided herein, in some embodiments, is a process for preparing a crystalline solid-state edisylate salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);97IPTS / 200140885.2Attorney Docket No. DCP-147WO(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) fdtering the mixture from step (vi) (e.g., via centrifugation) to obtain a solid precipitate; and(viii) drying the solid precipitate in (vii) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form.[000583] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ester. In some embodiments, the solvent in step (i) is ethyl acetate.[000584] In some embodiments, the acid in step (ii) is 1,2-ethanedisulfonic acid.[000585] In some embodiments, the solvent in step (v) is an aprotic solvent. In some embodiments, the solvent in step (v) is an ether. In some embodiments, the solvent in step (v) is tert-butyl methyl ether.Form IV[000586] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form IV, having an XRPD pattern comprising peaks, in terms of 2- theta, at about 14.54°, about 17.59°, and about 24.84°.[000587] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form IV, having an XRPD pattern comprising peaks, in terms of 2- theta, at about 14.5°, about 17.6°, and about 24.8°.[000588] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form IV, having an XRPD pattern comprising peaks, in terms of 2- theta, at about 13.92°, about 14.54°, about 17.59°, about 21.43°, and about 24.84°.[000589] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form IV, having an XRPD pattern comprising peaks, in terms of 2- theta, at about 13.9°, about 14.5°, about 17.6°, about 21.4°, and about 24.8°.98IPTS / 200140885.2Attorney Docket No. DCP-147WO[000590] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form IV, having an XRPD pattern comprising peaks, in terms of 2- theta, at about 13.92°, about 14.54°, about 17.59°, about 21.43°, about 24.84°, about 25.09°, and about 29.30°.[000591] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form IV, having an XRPD pattern comprising peaks, in terms of 2- theta, at about 13.9°, about 14.5°, about 17.6°, about 21.4°, about 24.8°, about 25.1°, and about 29.30°.[000592] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form IV, having an XRPD pattern substantially as shown in FIG. 6J.[000593] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form IV, having a TG / DSC thermogram substantially as shown in FIG. 6K.[000594] In some embodiments, the crystalline solid-state edisylate salt form is crystalline solid-state edisylate salt Form IV, having a 'H nuclear magnetic resonance (NMR) spectrum substantially as shown in FIG. 6L.[000595] In some embodiments, provided herein is a crystalline solid-state edisylate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) filtering the mixture from step (vi) (e.g, via centrifugation) to obtain a solid precipitate;(viii) drying the solid precipitate in (vii) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form; and99IPTS / 200140885.2Attorney Docket No. DCP-147WO(ix) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid-state form.[000596] In some embodiments, the solvent in step (v) is an aprotic solvent. In some embodiments, the solvent in step (v) is an ester. In some embodiments, the solvent in step (i) is ethyl acetate.[000597] In some embodiments, the acid in step (ii) is 1,2-ethanedisulfonic acid.[000598] In some embodiments, the solvent in step (v) is an aprotic solvent. In some embodiments, the solvent in step (v) is an ether. In some embodiments, the solvent in step (v) is tert-butyl methyl ether.[000599] In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound is substantially pure. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound is essentially free of solvents.[000600] In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has a chemical purity of greater than 99% by weight.[000601] In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more100IPTS / 200140885.2Attorney Docket No. DCP-147WO than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state edisylate salt Form IV of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000602] Also provided herein are pharmaceutical compositions comprising the crystalline solid-state edisylate salt Form IV of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000603] In some embodiments, the crystalline solid-state edisylate salt Form IV is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV is present in the composition in an amount of at101IPTS / 200140885.2Attorney Docket No. DCP-147WO least about 85% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV is present in the composition in an amount of at least about 96% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state edisylate salt Form IV is present in the composition in an amount of at least about 99% by weight.[000604] Also provided herein are pharmaceutical compositions consisting essentially of the crystalline solid-state edisylate salt Form IV of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000605] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state edisylate salt Form IV of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state edisylate salt Form IV of the compound represented by Formula (I), which is in the form of a tablet.[000606] Provided herein, in some embodiments, is a process for preparing a crystalline solid-state edisylate salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g, between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) filtering the mixture from step (vi) (e.g., via centrifugation) to obtain a solid precipitate;102IPTS / 200140885.2Attorney Docket No. DCP-147WO(viii) drying the solid precipitate in (vii) e.g., under reduced pressure (e.g, vacuum)) to obtain the crystalline solid-state form; and(ix) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid-state form.[000607] In some embodiments, the solvent in step (v) is an aprotic solvent. In some embodiments, the solvent in step (v) is an ester. In some embodiments, the solvent in step (i) is ethyl acetate.[000608] In some embodiments, the acid in step (ii) is 1,2-ethanedisulfonic acid.[000609] In some embodiments, the solvent in step (v) is an aprotic solvent. In some embodiments, the solvent in step (v) is an ether. In some embodiments, the solvent in step (v) is tert-butyl methyl ether.Cyclamate Sall Forms of the Compound of Formula (I)[000610] Provided herein, in some embodiments, are amorphous solid-state cyclamate salt forms of the compound represented by Formula (I):or a solvate thereof. In some embodiments, the amorphous solid-state cyclamate salt form has an XRPD pattern exhibiting a broad peak (halo pattern), in terms of 2-theta, that extends from about 10° to about 30°. In some embodiments, the amorphous solid-state cyclamate salt form has an XRPD pattern substantially as shown in FIG. 7A. In some embodiments, the amorphous solid- state cyclamate salt form has an XRPD pattern substantially as shown in FIG. 7B.[000611] In some embodiments, provided herein is an amorphous solid-state cyclamate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;103IPTS / 200140885.2Attorney Docket No. DCP-147WO(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the amorphous solid- state form.[000612] In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step (i) is an alcohol. In some embodiments, the solvent in step (i) is ethanol.[000613] In some embodiments, the acid in step (ii) is cyclamic acid.[000614] Provided herein, in some embodiments, is a process for preparing an amorphous solid-state cyclamate salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the amorphous solid- state form.[000615] In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step (i) is an alcohol. In some embodiments, the solvent in step (i) is ethanol.[000616] In some embodiments, the acid in step (ii) is cyclamic acid.104IPTS / 200140885.2Attorney Docket No. DCP-147WO[000617] In some embodiments, the amorphous solid-state cyclamate salt form of the compound is substantially pure. In some embodiments, the amorphous solid-state cyclamate salt form of the compound is essentially free of solvents.[000618] In some embodiments, the amorphous solid-state cyclamate salt form of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has a chemical purity of greater than 99% by weight.[000619] In some embodiments, the amorphous solid-state cyclamate salt form of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state cyclamate salt form of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a105IPTS / 200140885.2Attorney Docket No. DCP-147WO solvate thereof. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state cyclamate salt form of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid-state cyclamate salt form of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the amorphous solid- state cyclamate salt form of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000620] Also provided herein are pharmaceutical compositions comprising the amorphous solid-state cyclamate salt form of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000621] In some embodiments, the amorphous solid-state cyclamate salt form is present in the composition in an amount of at least about 80% by weight. In some embodiments, the amorphous solid-state cyclamate salt form is present in the composition in an amount of at least about 85% by weight. In some embodiments, the amorphous solid-state cyclamate salt form is present in the composition in an amount of at least about 90% by weight. In some embodiments, the amorphous solid-state cyclamate salt form is present in the composition in an amount of at least about 95% by weight. In some embodiments, the amorphous solid-state cyclamate salt form is present in the composition in an amount of at least about 96% by weight. In some embodiments, the amorphous solid-state cyclamate salt form is present in the composition in an amount of at least about 97% by weight. In some embodiments, the amorphous solid-state cyclamate salt form is present in the composition in an amount of at least about 98% by weight. In some embodiments, the amorphous solid-state cyclamate salt form is present in the composition in an amount of at least about 99% by weight.106IPTS / 200140885.2Attorney Docket No. DCP-147WO[000622] In some embodiments, provided herein is a pharmaceutical composition comprising the amorphous solid-state cyclamate salt form of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the amorphous solid-state cyclamate salt form of the compound represented by Formula (I), which is in the form of a tablet. In some embodiments, the composition is for oral administration.[000623] Also provided herein, in some embodiments, are pharmaceutical compositions consisting essentially of the amorphous solid-state cyclamate salt form described herein, or combinations thereof, and a pharmaceutically acceptable carrier. In some embodiments, the composition is for oral administration.[000624] Provided herein, in some embodiments, are crystalline solid-state cyclamate salt forms of the compound represented by Formula (I):or a solvate thereof.Form I[000625] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 6.44°, about 18.46°, and about 21.64°.[000626] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 6.4°, about 18.5°, and about 21.6°.[000627] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 6.44°, about 18.46°, about 19.42°, about 21.64°, and about 26.11°.107IPTS / 200140885.2Attorney Docket No. DCP-147WO[000628] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 6.4°, about 18.5°, about 19.4°, about 21.6°, and about 26.1°.[000629] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 6.44°, about 18.46°, about 19.42°, about 21.64°, about 26.11°, about 30.19°, and about 30.89°.[000630] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 6.4°, about 18.5°, about 19.4°, about 21.6°, about 26.1°, about 30.2°, and about 30.9°.[000631] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form I, having an XRPD pattern substantially as shown in FIG. 7E.[000632] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form I, having a TG / DSC thermogram substantially as shown in FIG. 7C.[000633] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form I, having a 'H nuclear magnetic resonance (NMR) spectrum substantially as shown in FIG. 7D.[000634] In some embodiments, provided herein is a crystalline solid-state cyclamate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid- state form.108IPTS / 200140885.2Attorney Docket No. DCP-147WO[000635] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ether, a ketone, an ester, or a haloalkane. In some embodiments, the solvent in step (i) is 2-MeTHF. In some embodiments, the solvent in step (i) is acetone. In some embodiments, the solvent in step (i) is ethyl acetate. In some embodiments, the solvent in step (i) is DCM.[000636] In some embodiments, the acid in step (ii) is cyclamic acid.[000637] In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound is substantially pure. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound is essentially free of solvents.[000638] In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has a chemical purity of greater than 99% by weight.[000639] In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state109IPTS / 200140885.2Attorney Docket No. DCP-147WO cyclamate salt Form I of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form I of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000640] Also provided herein are pharmaceutical compositions comprising the crystalline solid-state cyclamate salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000641] In some embodiments, the crystalline solid-state cyclamate salt Form I is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I is present in the composition in an amount of at least about 85% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I is present in the composition in an amount of at least about 96% by weight. In some110IPTS / 200140885.2Attorney Docket No. DCP-147WO embodiments, the crystalline solid-state cyclamate salt Form T is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form I is present in the composition in an amount of at least about 99% by weight.[000642] Also provided herein are pharmaceutical compositions consisting essentially of the crystalline solid-state cyclamate salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000643] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state cyclamate salt Form I of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state cyclamate salt Form I of the compound represented by Formula (I), which is in the form of a tablet.[000644] Provided herein, in some embodiments, is a process for preparing a crystalline solid-state cyclamate salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) (e.g., via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid- state form.[000645] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ether, a ketone, an ester, or a haloalkane. In some embodiments, the solvent in step (i) is 2-MeTHF. In some embodiments, the solvent in step (i) is acetone. In some embodiments, the solvent in step (i) is ethyl acetate. In some embodiments, the solvent in step (i) is DCM.[000646] In some embodiments, the acid in step (ii) is cyclamic acid.111IPTS / 200140885.2Attorney Docket No. DCP-147WOForm II[000647] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form II, having an XRPD pattern comprising peaks, in terms of 2- theta, at about 18.42°, about 20.26°, and about 24.67°.[000648] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form II, having an XRPD pattern comprising peaks, in terms of 2- theta, at about 18.4°, about 20.3°, and about 24.7°.[000649] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form II, having an XRPD pattern comprising peaks, in terms of 2- theta, at about 18.42°, about 18.58°, about 20.26°, about 21.61°, and about 24.67°.[000650] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form II, having an XRPD pattern comprising peaks, in terms of 2- theta, at about 18.4°, about 18.6°, about 20.3°, about 21.6°, and about 24.7°.[000651] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form II, having an XRPD pattern comprising peaks, in terms of 2- theta, at about 16.05°, about 18.42°, about 18.58°, about 18.93°, about 20.26°, about 21.61°, and about 24.67°.[000652] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form II, having an XRPD pattern comprising peaks, in terms of 2- theta, at about 16.1°, about 18.4°, about 18.6°, about 18.9°, about 20.3°, about 21.6°, and about 24.7°.[000653] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form II, having an XRPD pattern substantially as shown in FIG. 7F.[000654] In some embodiments, the crystalline solid-state cyclamate salt form is crystalline solid-state cyclamate salt Form II, having anuclear magnetic resonance (NMR) spectrum substantially as shown in FIG. 7G.[000655] In some embodiments, provided herein is a crystalline solid-state cyclamate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (1) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);112IPTS / 200140885.2Attorney Docket No. DCP-147WO(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) fdtering the mixture from step (vi) (e.g., via centrifugation) to obtain a solid precipitate; and(viii) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid-state form.[000656] In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step (i) is an alcohol. In some embodiments, the solvent in step (i) is ethanol.[000657] In some embodiments, the acid in step (ii) is cyclamic acid.[000658] In some embodiments, the solvent in step (v) is tert-butyl methyl ether.[000659] In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound is substantially pure. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound is essentially free of solvents.[000660] In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has a chemical purity of greater113IPTS / 200140885.2Attorney Docket No. DCP-147WO than 98% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has a chemical purity of greater than 99% by weight.[0006611 Insome embodiments, the crystalline solid-state cyclamate salt Form II of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state cyclamate salt Form II of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.114IPTS / 200140885.2Attorney Docket No. DCP-147WO[000662] Also provided herein are pharmaceutical compositions comprising the crystalline solid-state cyclamate salt Form II of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000663] In some embodiments, the crystalline solid-state cyclamate salt Form II is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II is present in the composition in an amount of at least about 85% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II is present in the composition in an amount of at least about 96% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state cyclamate salt Form II is present in the composition in an amount of at least about 99% by weight.[000664] Also provided herein are pharmaceutical compositions consisting essentially of the crystalline solid-state cyclamate salt Form II of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000665] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state cyclamate salt Form II of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state cyclamate salt Form II of the compound represented by Formula (I), which is in the form of a tablet.[000666] Provided herein, in some embodiments, is a process for preparing a crystalline solid-state cyclamate salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);115IPTS / 200140885.2Attorney Docket No. DCP-147WO(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) filtering the mixture from step (vi) (e.g., via centrifugation) to obtain a solid precipitate; and(viii) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid-state form.[000667] In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step (i) is an alcohol. In some embodiments, the solvent in step (i) is ethanol.[000668] In some embodiments, the acid in step (ii) is cyclamic acid.[000669] In some embodiments, the solvent in step (v) is tert-butyl methyl ether.Tos late Salt Forms of the Compound of Formula (I)[000670] Provided herein, in some embodiments, are amorphous solid-state tosylate salt forms of the compound represented by Formula (I):or a solvate thereof. [000671] Provided herein, in some embodiments, are crystalline solid-state tosylate salt forms of the compound represented by Formula (I):116IPTS / 200140885.2Attorney Docket No. DCP-147WOor a solvate thereof.Form I[000672] In some embodiments, the crystalline solid-state tosylate salt form is crystalline solid-state tosylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 16.20, about 18.58, and about 24.83°.[000673] In some embodiments, the crystalline solid-state tosylate salt form is crystalline solid-state tosylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 16.2, about 18.6, and about 24.8°.[000674] In some embodiments, the crystalline solid-state tosylate salt form is crystalline solid-state tosylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 8.50°, about 16.20°, about 18.58°, about 22.87°, and about 24.83°.[000675] In some embodiments, the crystalline solid-state tosylate salt form is crystalline solid-state tosylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 8.5°, about 16.2°, about 18.6°, about 22.9°, and about 24.8°.[000676] In some embodiments, the crystalline solid-state tosylate salt form is crystalline solid-state tosylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 8.50°, about 16.20°, about 17.90°, about 18.58°, about 21.55°, about 22.87°, and about 24.83°.[000677] In some embodiments, the crystalline solid-state tosylate salt form is crystalline solid-state tosylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 8.5°, about 16.2°, about 17.9°, about 18.6°, about 21.6°, about 22.9°, and about 24.8°.[000678] In some embodiments, the crystalline solid-state tosylate salt form is crystalline solid-state tosylate salt Form I, having an XRPD pattern substantially as shown in FIG. 8F.117IPTS / 200140885.2Attorney Docket No. DCP-147WO[000679] In some embodiments, the crystalline solid-state tosylate salt form is crystalline solid-state tosylate salt Form I, having a DSC thermogram substantially as shown in FIG. 8D. [000680] In some embodiments, the crystalline solid-state tosylate salt form is crystalline solid-state tosylate salt Form I, having a TG / DSC thermogram substantially as shown in FIG. 8C.[000681] In some embodiments, the crystalline solid-state tosylate salt form is crystalline solid-state tosylate salt Form I, having anuclear magnetic resonance (NMR) spectrum substantially as shown in FIG. 8E.[000682] In some embodiments, provided herein is a crystalline solid-state tosylate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g, between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) drying the solid precipitate in (iv) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form.[000683] In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step (i) is an alcohol. In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ether, a ketone, an ester, or a haloalkane. In some embodiments, the solvent in step (i) is 2-MeTHF. In some embodiments, the solvent in step (i) is acetone. In some embodiments, the solvent in step (i) is ethanol. In some embodiments, the solvent in step (i) is ethyl acetate. In some embodiments, the solvent in step (i) is DCM.[000684] In some embodiments, the acid in step (ii) is / oluenesulfonic acid.[000685] In some embodiments, provided herein is a crystalline solid-state tosylate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;118IPTS / 200140885.2Attorney Docket No. DCP-147WO(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) filtering the mixture from step (vi) (e.g., via centrifugation) to obtain a solid precipitate; and(viii) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid-state form.[000686] In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step (i) is an alcohol. In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is a ketone. In some embodiments, the solvent in step (i) is acetone. In some embodiments, the solvent in step (i) is ethanol.[000687] In some embodiments, the acid in step (ii) is / i-toluenesulfonic acid.[000688] In some embodiments, the solvent in step (v) is an aprotic solvent. In some embodiments, the solvent in step (v) is an ether. In some embodiments, the solvent in step (v) is tert-butyl methyl ether.[000689] In some embodiments, the crystalline solid-state tosylate salt Form I of the compound is substantially pure. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound is essentially free of solvents.[000690] In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has a chemical purity of greater than119IPTS / 200140885.2Attorney Docket No. DCP-147WO90% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has a chemical purity of greater than 96% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has a chemical purity of greater than 99% by weight.[000691] In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a120IPTS / 200140885.2Attorney Docket No. DCP-147WO solvate thereof. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state tosylate salt Form I of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000692] Also provided herein are pharmaceutical compositions comprising the crystalline solid-state tosylate salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000693] In some embodiments, the crystalline solid-state tosylate salt Form I is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I is present in the composition in an amount of at least about 85% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I is present in the composition in an amount of at least about 96% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state tosylate salt Form I is present in the composition in an amount of at least about 99% by weight.[000694] Also provided herein are pharmaceutical compositions consisting essentially of the crystalline solid-state tosylate salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000695] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state tosylate salt Form I of the compound represented by Formula (I), which is in the form of a capsule. In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state tosylate salt Form I of the compound represented by Formula (I), which is in the form of a tablet.[000696] Provided herein, in some embodiments, is a process for preparing a crystalline solid-state tosylate salt form of the compound of Formula (I), or a solvate thereof, comprising:121IPTS / 200140885.2Attorney Docket No. DCP-147WO(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) (e.g., via centrifugation) to obtain a solid precipitate; and(v) drying the solid precipitate in (iv) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form.[000697] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is an ether, a ketone, an ester, or a haloalkane. In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step(i) is an alcohol. In some embodiments, the solvent in step (i) is 2-MeTHF. In some embodiments, the solvent in step (i) is acetone. In some embodiments, the solvent in step (i) is ethanol. In some embodiments, the solvent in step (i) is ethyl acetate. In some embodiments, the solvent in step (i) is DCM.[000698] In some embodiments, the acid in step (ii) is / ?-toluenesulfonic acid.[000699] Provided herein, in some embodiments, is a process for preparing a crystalline solid-state tosylate salt form of the compound of Formula (I), or a solvate thereof, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) filtering the mixture from step (vi) (e.g., via centrifugation) to obtain a solid precipitate; and122IPTS / 200140885.2Attorney Docket No. DCP-147WO(viii) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid-state form.[000700] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is a ketone. In some embodiments, the solvent in step (i) is a protic solvent. In some embodiments, the solvent in step (i) is an alcohol. In some embodiments, the solvent in step (i) is acetone. In some embodiments, the solvent in step (i) is ethanol.[000701] In some embodiments, the acid in step (ii) is / 2-toluenesulfonic acid.[000702] In some embodiments, the solvent in step (v) is an aprotic solvent. In some embodiments, the solvent in step (v) is an ether. In some embodiments, the solvent in step (v) is tert-butyl methyl ether.Thiocyanate Salt Forms of the Compound of Formula (I)[000703] Provided herein, in some embodiments, are amorphous solid-state thiocyanate salt forms of the compound represented by Formula (I):or a solvate thereof.[000704] Provided herein, in some embodiments, are crystalline solid-state thiocyanate salt forms of the compound represented by Formula (I):123IPTS / 200140885.2Attorney Docket No. DCP-147WOor a solvate thereof.Form I[000705] In some embodiments, the crystalline solid-state thiocyanate salt form is crystalline solid-state thiocyanate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.44°, about 16.34°, and about 22.35°.[000706] In some embodiments, the crystalline solid-state thiocyanate salt form is crystalline solid-state thiocyanate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.4°, about 16.3°, and about 22.4°.[000707] In some embodiments, the crystalline solid-state thiocyanate salt form is crystalline solid-state thiocyanate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.44°, about 16.34°, about 21.30°, about 22.35°, and about 23.03°.[000708] In some embodiments, the crystalline solid-state thiocyanate salt form is crystalline solid-state thiocyanate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.4°, about 16.3°, about 21.3°, about 22.4°, and about 23.0°.[000709] In some embodiments, the crystalline solid-state thiocyanate salt form is crystalline solid-state thiocyanate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.44°, about 16.34°, about 19.73°, about 21.30°, about 22.35°, about 23.03°, and about 31.65°.[000710] In some embodiments, the crystalline solid-state thiocyanate salt form is crystalline solid-state thiocyanate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 12.4°, about 16.3°, about 19.7°, about 21.3°, about 22.4°, about 23.0°, and about 31.65°.124IPTS / 200140885.2Attorney Docket No. DCP-147WO[000711] In some embodiments, the crystalline solid-state thiocyanate salt form is crystalline solid-state thiocyanate salt Form I, having an XRPD pattern substantially as shown in FIG. 9D.[000712] In some embodiments, provided herein is a crystalline solid-state thiocyanate salt form of the compound of Formula (I), or a solvate thereof, produced by a process comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) fdtering the mixture from step (iii) e.g., via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid- state form.[000713] In some embodiments, the solvent in step (i) is an aprotic solvent. In some embodiments, the solvent in step (i) is a haloalkane. In some embodiments, the solvent in step (i) is DCM.[000714] In some embodiments, the acid in step (ii) is thiocyanic acid.[000715] In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound is substantially pure. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound is essentially free of solvents.[000716] In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has a chemical purity of greater than 75% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has a chemical purity of greater than 80% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has a chemical purity of greater than 85% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has a chemical purity of greater than 90% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has a chemical purity of greater than 95% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has a chemical purity of greater125IPTS / 200140885.2Attorney Docket No. DCP-147WO than 96% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has a chemical purity of greater than 97% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has a chemical purity of greater than 98% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has a chemical purity of greater than 99% by weight.[000717] In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has no more than about 10 mol%, no more than about 9 mol%, no more than about 8 mol%, no more than about 7 mol%, no more than about 6 mol%, no more than about 5 mol%, no more than about 4 mol%, no more than about 3 mol%, no more than about 2 mol%, or no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has no more than about 10 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has no more than about 9 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has no more than about 8 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has no more than about 7 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has no more than about 6 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has no more than about 5 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has no more than about 4 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has no more than about 3 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof. In some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has no more than about 2 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate126IPTS / 200140885.2Attorney Docket No. DCP-147WO thereof. Tn some embodiments, the crystalline solid-state thiocyanate salt Form I of the compound has no more than about 1 mol% of other solid-state forms of the compound represented by Formula (I), or a solvate thereof.[000718] Also provided herein are pharmaceutical compositions comprising the crystalline solid-state thiocyanate salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000719] In some embodiments, the crystalline solid-state thiocyanate salt Form I is present in the composition in an amount of at least about 80% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I is present in the composition in an amount of at least about 85% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I is present in the composition in an amount of at least about 90% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I is present in the composition in an amount of at least about 95% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I is present in the composition in an amount of at least about 96% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I is present in the composition in an amount of at least about 97% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I is present in the composition in an amount of at least about 98% by weight. In some embodiments, the crystalline solid-state thiocyanate salt Form I is present in the composition in an amount of at least about 99% by weight.[000720] Also provided herein are pharmaceutical compositions consisting essentially of the crystalline solid-state thiocyanate salt Form I of the compound represented by Formula (I) and a pharmaceutically acceptable excipient or carrier.[000721] In some embodiments, provided herein is a pharmaceutical composition comprising the crystalline solid-state thiocyanate salt Form I of the compound represented by Formula (I), whi...

Claims

1. Attorney Docket No. DCP-147WOCLAIMSWe claim:

1. A salt form of the compound represented by Formula (I):

2. The salt form of claim 1, wherein the salt is selected from the group consisting of hydrobromide, hydrochloride, napadisylate, sulfate, edisylate, cyclamate, tosylate, thiocyanate, mesylate, napsylate, besylate, oxalate, aspartate, maleate, pamoate, malonate, gentisate, salicylate, tartrate, fumarate, mandelate, malate, benzoate, succinate, and acetate.

3. The salt form of claim 1 or 2, wherein the salt is selected from the group consisting of hydrobromide, napadisylate, tartrate, napsylate, malate, gentisate, fumarate, and pamoate.

4. The salt form of any one of claims 1-3, wherein the salt is selected from hydrobromide, malate, fumarate, and tartrate.

5. A pharmaceutical composition comprising the salt form of any one of claims 1-4, or combinations thereof, and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition consisting essentially of the salt form of any one of claims 1-4, or combinations thereof, and a pharmaceutically acceptable carrier.

7. The pharmaceutical composition of claim 5 or 6, wherein the composition is for oral administration.

8. A solid-state salt form of the compound represented by Formula (I):678IPTS / 200140885.2Attorney Docket No. DCP-147WO9. The solid-state salt form of claim 8, wherein the solid-state salt form is amorphous.

10. A crystalline solid-state salt form of compound represented by Formula (I):

11. The crystalline solid-state salt form of claim 10, wherein the salt is selected from the group consisting of hydrobromide, hydrochloride, napadisylate, sulfate, edisylate, cyclamate, tosylate, thiocyanate, mesylate, napsylate, besylate, oxalate, aspartate, maleate, pamoate, malonate, gentisate, salicylate, tartrate, fumarate, mandelate, malate, benzoate, succinate, and acetate.

12. The crystalline solid-state salt form of claim 10 or 11, wherein the salt is selected from the group consisting of hydrobromide, napadisylate, tartrate, napsylate, malate, gentisate, fumarate, and pamoate.

13. The crystalline solid-state salt form of any one of claims 10-12, wherein the salt is selected from hydrobromide, malate, fumarate, and tartrate.

14. A pharmaceutical composition comprising the crystalline solid-state salt form of any one of claims 10-13, or combinations thereof, and a pharmaceutically acceptable carrier.

15. A pharmaceutical composition consisting essentially of the crystalline solid-state salt form of any one of claims 10-13, or combinations thereof, and a pharmaceutically acceptable earner.679IPTS / 200140885.2Attorney Docket No. DCP-147WO16. The pharmaceutical composition of claim 14 or 15, wherein the composition is for oral administration.

17. A crystalline solid-state hydrobromide salt form of the compound represented by Formula (I):

18. The crystalline solid-state hydrobromide salt form of the compound of claim 17, which is crystalline solid-state hydrobromide salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 7.44°, about 18.15°, and about 19.28°.

19. The crystalline solid-state hydrobromide salt form of the compound of claim 17 or 18, which is crystalline solid-state hydrobromide salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 7.44°, about 18.15°, about 18.79°, about 19.28°, and about 23.87°.

20. The crystalline solid-state hydrobromide salt form of the compound of any one of claims 17-19, which is crystalline solid-state hydrobromide salt Form II, having an X-ray powder diffraction (XRPD) pattern comprising peaks, in terms of 2-theta, at about 7.44°, about 14.91°, about 18.15°, about 18.79°, about 19.28°, about 23.87°, and about 26.46°.

21. The crystalline solid-state hydrobromide salt form of the compound of any one of claims 17-20, which is crystalline solid-state hydrobromide salt Form II, having an XRPD pattern substantially as shown in FIG. 2A.

22. The crystalline solid-state hydrobromide salt form of the compound of any one of claims 17-21, which is crystalline solid-state hydrobromide salt Form II, having a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at about 210 °C.

23. The crystalline solid-state hydrobromide salt form of the compound of any one of claims 17-21, which is crystalline solid-state hydrobromide salt Form II, having a DSC thermogram substantially as shown in FIG. 2C.680IPTS / 200140885.2Attorney Docket No. DCP-147WO24. The crystalline solid-state hydrobromide salt form of the compound of any one of claims 17-21, which is crystalline solid-state hydrobromide salt Form II, having a thermogravimetric / differential scanning calorimetry (TG / DSC) thermogram substantially as shown in FIG. 2B.

25. The crystalline solid-state hydrobromide salt form of the compound of any one of claims 17-21, which is crystalline solid-state hydrobromide salt Form II, having arH nuclear magnetic resonance (NMR) spectrum substantially as shown in FIG. 2G.

26. The crystalline solid-state hydrobromide salt form of the compound of any one of claims 17-25, which is crystalline solid-state hydrobromide salt Form II, wherein the crystalline solid- state salt form is a hydrate.

27. The crystalline solid-state hydrobromide salt form of claim 26, wherein the hydrate is a monohydrate.

28. A process for preparing the crystalline solid-state hydrobromide salt form of any one of claims 17-27, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g, at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid- state form.

29. The process of claim 28, wherein the solvent in step (i) is ethyl acetate.

30. The process of claim 28 or 29, wherein the acid in step (ii) is hydrobromic acid.

31. A crystalline solid-state hydrobromide salt form of the compound represented by Formula (I) produced by the process of any one of claims 28-30.

32. A crystalline solid-state fumarate salt form of the compound represented by Formula (I):681IPTS / 200140885.2Attorney Docket No. DCP-147WO33. The crystalline solid-state fumarate salt form of the compound of claim 32, which is crystalline solid-state fumarate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 19.31°, about 19.50°, and about 23.42°.

34. The crystalline solid-state fumarate salt form of the compound of claim 32 or 33, which is crystalline solid-state fumarate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 11.54°, about 13.56°, about 19.31°, about 19.50°, and about 23.42°.

35. The crystalline solid-state fumarate salt form of the compound of any one of claims 32-34, which is crystalline solid-state fumarate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 11.54°, about 13.56°, about 17.55°, about 18.49°, about 19.31 °, about 19.50°, and about 23.42°.

36. The crystalline solid-state fumarate salt form of the compound of any one of claims 32-35, which is crystalline solid-state fumarate salt Form I, having an XRPD pattern substantially as shown in FIG. 35 A.

37. The crystalline solid-state fumarate salt form of the compound of any one of claims 32-36, which is crystalline solid-state fumarate salt Form I, having a DSC thermogram comprising an endothermic peak at about 163 °C.

38. The crystalline solid-state fumarate salt form of the compound of any one of claims 32- 36, which is crystalline solid-state fumarate salt Form I, having a DSC thermogram substantially as shown in FIG. 35C.

39. The crystalline solid-state fumarate salt form of the compound of any one of claims 32- 36, which is crystalline solid-state fumarate salt Form I, having a TG / DSC thermogram substantially as shown in FIG. 35B.682IPTS / 200140885.2Attorney Docket No. DCP-147WO40. The crystalline solid-state fumarate salt form of the compound of any one of claims 32-36, which is crystalline solid-state fumarate salt Form I, having aNMR spectrum substantially as shown in FIG. 35G.

41. The crystalline solid-state fumarate salt form of the compound of any one of claims 32-40, which is crystalline solid-state fumarate salt Form I, wherein the crystalline solid-state salt form is a hydrate.

42. The crystalline solid-state fumarate salt form of claim 41, wherein the hydrate is a monohydrate.

43. A process for preparing the crystalline solid-state fumarate salt form of any one of claims 32-42, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g, between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) filtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and(v) drying the solid precipitate in (iv) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form.

44. The process of claim 43, wherein the solvent in step (i) is 2-methyltetrahydrofuran.

45. The process of claim 43 or 44, wherein the acid in step (ii) is fumaric acid.

46. A crystalline solid-state fumarate salt form of the compound represented by Formula (I) produced by the process of any one of claims 43-45.

47. A crystalline solid-state malate salt form of the compound represented by Formula (I):683IPTS / 200140885.2Attorney Docket No. DCP-147WO48. The crystalline solid-state malate salt form of the compound of claim 47, which is crystalline solid-state malate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 16.44°, about 19.62°, and about 23.15°.

49. The crystalline solid-state malate salt form of the compound of claim 47 or 48, which is crystalline solid-state malate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 13.65°, about 16.44°, about 19.07°, about 19.62°, and about 23.15°.

50. The crystalline solid-state malate salt form of the compound of any one of claims 47-49, which is crystalline solid-state malate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 11.18°, about 13.65°, about 15.75°, about 16.442°, about 19.07°, about 19.62°, and about 23.15°.

51. The crystalline solid-state malate salt form of the compound of any one of claims 47-50, which is crystalline solid-state malate salt Form I, having an XRPD pattern substantially as shown in FIG. 40A.

52. The crystalline solid-state malate salt form of the compound of any one of claims 47-51, which is crystalline solid-state malate salt Form I, having a DSC thermogram comprising an endothermic peak at about 158 °C.

53. The crystalline solid-state malate salt form of the compound of any one of claims 47-51, which is crystalline solid-state malate salt Form I, having a DSC thermogram substantially as shown in FIG. 40C.

54. The crystalline solid-state malate salt form of the compound of any one of claims 47-51, which is crystalline solid-state malate salt Form I, having a TG / DSC thermogram substantially as shown in FIG. 40B.

55. The crystalline solid-state malate salt form of the compound of any one of claims 47-51, which is crystalline solid-state malate salt Form I, having a 'l l NMR spectrum substantially as shown in FIG. 40G.

56. The crystalline solid-state malate salt form of the compound of any one of claims 47-55, which is crystalline solid-state malate salt Form I, wherein the crystalline solid-state salt form is a hydrate.

57. The crystalline solid-state malate salt form of claim 56, wherein the hydrate is a monohydrate.684IPTS / 200140885.2Attorney Docket No. DCP-147WO58. A process for preparing the crystalline solid-state malate salt form of any one of claims 47-57, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g, between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) fdtering the mixture from step (vi) (e.g, via centrifugation) to obtain a solid precipitate; and(v) drying the solid precipitate in (vii) (e.g, under reduced pressure (e.g, vacuum)) to obtain the crystalline solid-state form.

59. The process of claim 58 wherein the solvent in step (i) is 2-methyltetrahydrofuran.

60. The process of claim 58 or 59, wherein the acid in step (ii) is L-malic acid.

61. The process of any one of claims 58-60, wherein the solvent in step (v) is tert-butyl methyl ether.

62. A crystalline solid-state malate salt form of the compound represented by Formula (I) produced by the process of any one of claims 58-61.

63. A crystalline solid-state tartrate salt form of the compound represented by Formula (I):685IPTS / 200140885.2Attorney Docket No. DCP-147WO64. The crystalline solid-state tartrate salt form of the compound of claim 63, which is crystalline solid-state tartrate salt Form III, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 14.16°, about 15.97°, and about 18.82°.

65. The crystalline solid-state tartrate salt form of the compound of claim 63 or 64, which is crystalline solid-state tartrate salt Form III, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 11.71°, about 14.16°, about 15.97°, about 18.82°, and about 24.62°.

66. The crystalline solid-state tartrate salt form of the compound of any one of claims 63-65, which is crystalline solid-state tartrate salt Form III, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 11.71°, about 14.16°, about 15.97°, about 17.08°, about 18.82°, about 21.14°, and about 24.62°.

67. The crystalline solid-state tartrate salt form of the compound of any one of claims 63-66, which is crystalline solid-state tartrate salt Form III, having an XRPD pattern substantially as shown in FIG. 26J.

68. The crystalline solid-state tartrate salt form of the compound of any one of claims 63-67, which is crystalline solid-state tartrate salt Form III, having a DSC thermogram comprising an endothermic peak at about 183 °C.

69. The crystalline solid-state tartrate salt form of the compound of any one of claims 63-67, which is crystalline solid-state tartrate salt Form III, having a DSC thermogram substantially as shown in FIG. 26C.

70. The crystalline solid-state tartrate salt form of the compound of any one of claims 63-67, which is crystalline solid-state tartrate salt Form III, having a TG / DSC thermogram substantially as shown in FIG. 26B.

71. The crystalline solid-state tartrate salt form of the compound of any one of claims 63-67, which is crystalline solid-state tartrate salt Form III, having a 'l l NMR spectrum substantially as shown in FIG. 37G.

72. A process for preparing the crystalline solid-state tartrate salt form of any one of claims 63-71, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);686IPTS / 200140885.2Attorney Docket No. DCP-147WO(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 72 hours);(iv) filtering the mixture from step (iii) to obtain a solid precipitate; and(v) drying the solid precipitate in (iv) (e.g., under reduced pressure (e.g., vacuum)) to obtain the crystalline solid-state form.

73. The process of claim 72, wherein the solvent in step (i) is ethanol.

74. The process of claim 72 or 73, wherein the acid in step (ii) is L-tartaric acid.

75. A crystalline solid-state tartrate salt form of the compound represented by Formula (I) produced by the process of any one of claims 72-74.

76. A crystalline solid-state napadisylate salt form of the compound represented by Formula (I):

77. The crystalline solid-state napadisylate salt form of the compound of claim 76, which is crystalline solid-state napadisylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 8.38°, about 16.03°, and about 16.16°.

78. The crystalline solid-state napadisylate salt form of the compound of claim 76 or 77, which is crystalline solid-state napadisylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 8.38°, about 16.03°, about 16.16°, about 23.09°, and about 25.10°.

79. The crystalline solid-state napadisylate salt form of the compound of any one of claims 76-78, which is crystalline solid-state napadisylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 8.38°, about 16.03°, about 16.16°, about 18.03°, about 23.09°, about 25.10°, and about 26.62°.687IPTS / 200140885.2Attorney Docket No. DCP-147WO80. The crystalline solid-state napadisylate salt form of the compound of any one of claims 76-79, which is crystalline solid-state napadisylate salt Form I, having an XRPD pattern substantially as shown in FIG. 4F.

81. The crystalline solid-state napadisylate salt form of the compound of any one of claims 76-80, which is crystalline solid-state napadisylate salt Form I, having a DSC thermogram comprising an endothermic peak at about 139 °C.

82. The crystalline solid-state napadisylate salt form of the compound of any one of claims 76-80, which is crystalline solid-state napadisylate salt Form I, having a DSC thermogram substantially as shown in FIG. 4D.

83. The crystalline solid-state napadisylate salt form of the compound of any one of claims 76-80, which is crystalline solid-state napadisylate salt Form I, having a TG / DSC thermogram substantially as shown in FIG. 4C.

84. The crystalline solid-state napadisylate salt form of the compound of any one of claims 76-80, which is crystalline solid-state napadisylate salt Form I, having a 'H NMR spectrum substantially as shown in FIG. 4E.

85. The crystalline solid-state napadisylate salt form of the compound of any one of claims 76-84, which is crystalline solid-state napadisylate salt Form I, wherein the crystalline solid-state salt form is a hydrate.

86. The crystalline solid-state napadisylate salt form of claim 85, wherein the hydrate is a monohydrate87. A process for preparing the crystalline solid-state napadisylate salt form of any one of claims 76-86, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g, between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) (e.g, via centrifugation) to obtain a solid precipitate; and688IPTS / 200140885.2Attorney Docket No. DCP-147WO(v) storing the precipitate at an elevated temperature and relative humidity (RH) (e.g.. at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid- state form.

88. The process of claim 87, wherein the solvent in step (i) is selected from the group consisting of 2-methyltetrahydrofuran, acetone, ethanol, ethyl acetate, methyl ethyl ketone, and dichloromethane.

89. The process of claim 87 or 88, wherein the solvent in step (i) is 2-methyltetrahydrofuran.

90. The process of any one of claims 87-89, wherein the acid in step (ii) is 1,5- naphthalenedisulfonic acid.

91. A crystalline solid-state napadisylate salt form of the compound represented by Formula (I) produced by the process of any one of claims 87-90.

92. A crystalline solid-state napsylate salt form of the compound represented by Formula (I):

93. The crystalline solid-state napsylate salt form of the compound of claim 92, which is crystalline solid-state napsylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 18.75°, about 19.26°, and about 24.26°.

94. The crystalline solid-state napsylate salt form of the compound of claim 92 or 93, which is crystalline solid-state napsylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 18.68°, about 18.75°, about 19.26°, about 22.50°, and about 24.26°.

95. The crystalline solid-state napsylate salt form of the compound of any one of claims 92- 94, which is crystalline solid-state napsylate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 18.68°, about 18.75°, about 18.86°, about 19.26°, about 22.50°, about 24.01°, and about 24.26°.689IPTS / 200140885.2Attorney Docket No. DCP-147WO96. The crystalline solid-state napsylate salt form of the compound of any one of claims 92-95, which is crystalline solid-state napsylate salt Form I, having an XRPD pattern substantially as shown in FIG. 1 IF.

97. The crystalline solid-state napsylate salt form of the compound of any one of claims 92-96, which is crystalline solid-state napsylate salt Form I, having a DSC thermogram comprising an endothermic peak at about 127 °C.

98. The crystalline solid-state napsylate salt form of the compound of any one of claims 92-96, which is crystalline solid-state napsylate salt Form I, having a DSC thermogram substantially as shown in FIG. 1 ID.

99. The crystalline solid-state napsylate salt form of the compound of any one of claims 92-96, which is crystalline solid-state napsylate salt Form I, having a TG / DSC thermogram substantially as shown in FIG. 11C.

100. The crystalline solid-state napsylate salt form of the compound of any one of claims 92-96, which is crystalline solid-state napsylate salt Form I, having arH NMR spectrum substantially as shown in FIG. 1 IE.

101. The crystalline solid-state napsylate salt form of the compound of any one of claims 92- 100, which is crystalline solid-state napsylate salt Form I, wherein the crystalline solid-state salt form is a hydrate.

102. The crystalline solid-state napsylate salt form of claim 101, wherein the hydrate is a monohydrate.

103. A process for preparing the crystalline solid-state napsylate salt form of any one of claims 92-102, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g, between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) evaporating the solvent from the mixture in (iii) to obtain a solid precipitate; and(v) storing the precipitate at about an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid-state form.690IPTS / 200140885.2Attorney Docket No. DCP-147WO104. The process of claim 103, wherein the solvent in step (i) is selected from the group consisting of 2-methyltetrahydrofuran, acetone, ethyl acetate, methyl ethyl ketone, and dichloromethane.

105. The process of claim 103 or 104, wherein the solvent in step (i) is 2- methyltetrahydrofuran.

106. The process of any one of claims 103-105, wherein the acid in step (ii) is 1,5- naphthalene-2-sulfonic acid.

107. A crystalline solid-state napsylate salt form of the compound represented by Formula (I) produced by the process of any one of claims 103-106.

108. A crystalline solid-state gentisate salt form of the compound represented by Formula (I):

109. The crystalline solid-state gentisate salt form of the compound of claim 108, which is crystalline solid-state gentisate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 14.96°, about 22.35°, and about 19.51°.

110. The crystalline solid-state gentisate salt form of the compound of claim 108 or 109, which is crystalline solid-state gentisate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 14.96°, about 16.83°, about 20.14°, about 22.35°, and about 19.51°.

111. The crystalline solid-state gentisate salt form of the compound of any one of claims 108-110, which is crystalline solid-state gentisate salt Form II, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 6.34°, about 10.26°, about 14.96°, about 16.83°, about 19.51°, about 20.14°, and about 22.35°.

112. The crystalline solid-state gentisate salt form of the compound of any one of claims 108-111, which is crystalline solid-state gentisate salt Form II, having an XRPD pattern substantially as shown in FIG. 2 IF.691IPTS / 200140885.2Attorney Docket No. DCP-147WO113. The crystalline solid-state gentisate salt form of the compound of any one of claims 108-112, which is crystalline solid-state gentisate salt Form II, having a TG / DSC thermogram comprising an endothermic peak at about 167 °C.

114. The crystalline solid-state gentisate salt form of the compound of any one of claims 108-112, which is crystalline solid-state gentisate salt Form II, having a TG / DSC thermogram substantially as shown in FIG. 21G.

115. The crystalline solid-state gentisate salt form of the compound of any one of claims 108-112, which is crystalline solid-state gentisate salt Form II, having arH NMR spectrum substantially as shown in FIG. 21H.

116. A process for preparing the crystalline solid-state gentisate salt form of any one of claims 108-115, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 24 hours);(iv) evaporating the remaining solvent from the mixture in (iii);(v) adding a solvent to the mixture in (iv);(vi) temperature cycling the mixture from step (v) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(vii) fdtering the mixture from step (vi) (e.g., via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at about an elevated temperature and relative humidity (RH) (e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid-state form.

117. The process of claim 116, wherein the solvent in step (i) is ethyl acetate.

118. The process of claim 116 or 117, wherein the acid in step (ii) is 2,5 -dihydroxybenzoic acid.

119. The process of any one of claims 116-118, wherein the solvent in step (v) is tert-butyl methyl ether.692IPTS / 200140885.2Attorney Docket No. DCP-147WO120. A crystalline solid-state gentisate salt form of the compound represented by Formula (I) produced by the process of any one of claims 116-119.

121. A crystalline solid-state pamoate salt form of the compound represented by Formula (I):

122. The crystalline solid-state pamoate salt form of the compound of claim 121, which is crystalline solid-state pamoate salt Form I, having an XRPD pattern comprising peaks, in terms of2-theta, at about 19.00°, about 20.32°, and about 21.44°.

123. The crystalline solid-state pamoate salt form of the compound of claim 121 or 122, which is crystalline solid-state pamoate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 5.85°, about 8.15°, about 19.00°, about 20.32°, and about 21.44°.

124. The crystalline solid-state pamoate salt form of the compound of any one of claims 121 -123, which is crystalline solid-state pamoate salt Form I, having an XRPD pattern comprising peaks, in terms of 2-theta, at about 5.85°, about 6.81°, about 8.15°, about 17.56°, about 19.00°, about 20.32°, and about 21.44°.

125. The crystalline solid-state pamoate salt form of the compound of any one of claims 121-124, which is crystalline solid-state pamoate salt Form I, having an XRPD pattern substantially as shown in FIG. 18G.

126. The crystalline solid-state pamoate salt form of the compound of any one of claims 121-125, which is crystalline solid-state pamoate salt Form I, having a TG / DSC thermogram comprising an endothermic peak at about 181 °C.

127. The crystalline solid-state pamoate salt form of the compound of any one of claims 121- 125, which is crystalline solid-state pamoate salt Form I, having a TG / DSC thermogram substantially as shown in FIG. 18C.693IPTS / 200140885.2Attorney Docket No. DCP-147WO128. The crystalline solid-state pamoate salt form of the compound of any one of claims 121-125, which is crystalline solid-state pamoate salt Form I, having aJH NMR spectrum substantially as shown in FIG. 18D.

129. A process for preparing the crystalline solid-state pamoate salt form of any one of claims 121-128, comprising:(i) providing a mixture of a compound represented by Formula (I) and a solvent;(ii) adding an acid to the mixture of the compound represented by Formula (I) and the solvent from step (i);(iii) temperature cycling the mixture from step (ii) (e.g., between ambient temperature and about 40 °C in about 4-hour cycles for about 48 hours);(iv) filtering the mixture from step (iii) e.g., via centrifugation) to obtain a solid precipitate; and(v) storing the precipitate at about an elevated temperature and relative humidity (RH) e.g., at about 40 °C / about 75% relative humidity (RH)) to obtain the crystalline solid-state form.

130. The process of claim 129, wherein the solvent in step (i) is selected from the group consisting of 2-methyltetrahydrofuran, methyl ethyl ketone, and dichloromethane.

131. The process of claim 129 or 130, wherein the solvent in step (i) is 2- methyltetrahydrofuran.

132. The process of any one of claims 129-131, wherein the acid in step (ii) is pamoic acid.

133. A crystalline solid-state pamoate salt form of the compound represented by Formula (I) produced by the process of any one of claims 129-132.

134. The crystalline solid-state form of the compound of any one of claims 10-13, 17-27, 31- 42, 46-57, 62-71, 75-86, 91-102, 107-115, 120-128, and 133, which is substantially pure.

135. The crystalline solid-state form of the compound of claim 134, which has a chemical purity of greater than 90% by weight.

136. The crystalline solid-state form of the compound of claim 134 or 135, which has a chemical purity of greater than 95% by weight.

137. The crystalline solid-state form of the compound of any one of claims 134-136, which has a chemical purity of greater than 97% by weight.694IPTS / 200140885.2Attorney Docket No. DCP-147WO138. The crystalline solid-state form of the compound of any one of claims 134-137, which has a chemical purity of greater than 99% by weight.

139. The crystalline solid-state salt form of any one of claims 10-13, 17-27, 31-42, 46-57, 62- 71, 75-86, 91-102, 107-115, 120-128, and 133, having not more than about 5 mol%, not more than about 3 mol%, or not more than about 1 mol% of other solid-state forms of the compound represented by Formula (I).

140. The crystalline solid-state form of any one of claims 10-13, 17-27, 31-42, 46-57, 62-71, 75-86, 91-102, 107-115, 120-128, and 133, which is essentially free of solvents.

141. A pharmaceutical composition comprising the crystalline solid-state salt form of any one of claims 10-13, 17-27, 31-42, 46-57, 62-71, 75-86, 91-102, 107-115, 120-128, and 133, or a combination thereof, and a pharmaceutically acceptable excipient or carrier.

142. The pharmaceutical composition of claim 141, wherein the crystalline solid-state salt form is present in the composition in an amount of at least about 90% by weight.

143. A pharmaceutical composition consisting essentially of the crystalline solid-state salt form of any one of claims 10-13, 17-27, 31-42, 46-57, 62-71, 75-86, 91-102, 107-115, 120-128, and 133, or a combination thereof, and a pharmaceutically acceptable excipient or carrier.

144. A method of treating a disease or disorder in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the crystalline solid-state form of the compound of any one of claims 10-13, 17-27, 31-42, 46-57, 62-71, 75-86, 91-102, 107- 115, 120-128, and 133, or of the pharmaceutical composition of any one of claims 141-143.

145. The method of claim 144, wherein the disease or disorder is cancer.

146. The method of claim 145, wherein the cancer is selected from the group consisting of gastrointestinal stromal tumors, esophageal cancer, gastric cancer, melanomas, gliomas, glioblastomas, gynecological cancers, bladder cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, renal cancers, hepatic cancers, osteosarcomas, Ewing sarcoma, multiple myelomas, cervical carcinomas, cancers that are metastatic to bone, papillary thyroid carcinoma, colorectal cancer, acute myeloid leukemia, relapsed acute myeloid leukemia, refractory acute myeloid leukemia, myelodysplastic syndrome, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, and mantle cell lymphoma.

147. The method of any one of claims 144-146, further comprising administering to the patient one or more additional therapeutic agents.695IPTS / 200140885.2Attorney Docket No. DCP-147WO148. The method of claim 147, wherein the one or more additional therapeutic agents is selected from the group consisting of a MAP kinase pathway inhibitor, an EGFR inhibitor, a KIT inhibitor, a FLT3 inhibitor, and combinations thereof.

149. The method of claim 148, wherein the MAP kinase pathway inhibitor is selected from the group consisting of a MEK inhibitor, an ERK inhibitor, a RAF inhibitor, and a Ras inhibitor, and combinations thereof.

150. The method of claim 149, wherein the MEK inhibitor is selected from the group consisting of trametinib, selumetinib, cobimetinib, binimetinib, avutometinib, mirdametinib, pimasertib, refametinib, and pelitinib, and pharmaceutically acceptable salts thereof.

151. The method of claim 149, wherein the ERK inhibitor is selected from the group consisting of ulixertinib, SCH772984, LY3214996, ravoxertinib, and VX-l le, and pharmaceutically acceptable salts thereof.

152. The method of claim 149, wherein the RAF inhibitor is selected from the group consisting of LY3009120, LXH254 (naporafenib), RAF709, KIN-2787 (exarafenib), dabrafenib, vemurafenib, encorafenib, tovorafenib, PLX8394, agerafenib, lifirafenib, belvarafenib, uplarafenib, JZP815, BDTX-4933, and DCC-3084, and pharmaceutically acceptable salts thereof.

153. The method of claim 149, wherein the Ras inhibitor is selected from the group consisting of sotorasib (AMG-510), adagrasib (MRTX849), LY3537982, opnurasib, divarasib (GDC-6036), fulzerasib, MRTX-1133, JAB-21822, GFH925, ELI-002, RMC-6236, ASP3082, YL-17231, QTX3034, RMC-9805, HRS-4642, RMC-8839, INCB161734, and RMC-6291, and pharmaceutically acceptable salts thereof.

154. The method of claim 148, wherein the EGFR inhibitor is selected from the group consisting of cetuximab, osimertinib, gefitinib, lapatinib, erlotinib, dacomitinib, neratinib, and afatinib, and pharmaceutically acceptable salts thereof.

155. The method of claim 148, wherein the KIT inhibitor is selected from the group consisting of ripretinib, avapritinib, sunitinib, AZD3229 (NB003), THE-630, imatinib, midostaurin, bezuclastinib, olverembatinib (HQP1351), famitinib, IDRX-42 (M4205), elenestinib, BLU-808, IDRX-73, SLRN-517, THB335, DCC-3009, pexidartinib, and regorafenib, and pharmaceutically acceptable salts thereof.696IPTS / 200140885.2Attorney Docket No. DCP-147WO156. The method of claim 148, wherein the FLT3 inhibitor is selected from the group consisting of midostaurin, lestaurtinib, ponatinib, tandutinib, quizartinib , and gilteritinib, and pharmaceutically acceptable salts thereof.

157. The method of claim 147, wherein the additional therapeutic agent is a chemotherapeutic agent.

158. The method of claim 157, wherein the chemotherapeutic agent is a selected from the group consisting of anti-tubulin agents, vinorelbine, DNA-alkylating agents, DNA intercalating agents, 5 -fluorouracil, capecitabine, cytarabine, decitabine, 5-aza cytadine, gemcitabine, and methotrexate.697IPTS / 200140885.2

Images